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ABSTRACT
Previous abusive clinical trials have caused several obstacles in recruiting African 
Americans for clinical trials today. The memory of the Tuskegee Syphilis Study alone 
remains a hard pill to swallow and is a constant hindrance to recruiting potential African 
Americans specifically males, for clinical trials. The basic trust that African Americans 
have for physician researchers, U. S. government doctors, U. S. government-sponsored 
research, and biomedical research in general has been seriously, although not irrevocably, 
breached.
The purpose of this study was to gain an understanding of the knowledge, attitudes, 
and beliefs African Americans have that support decisions to either participate or not 
participate in a clinical trial. Specific areas that were examined by perceptual and demo­
graphic measures included: knowledge of clinical research processes, perceptions of 
clinical research purposes and procedures, advantages and disadvantages for the 
individual of participation in clinical research trials, characteristics of current and past 
participation in clinical research trials, exposure to selected experiences which are 
preliminary to participation in clinical research trials, perceptions regarding the need for 
selected changes in preparation for participation in clinical research trials; and selected 
personal demographic characteristics: gender, age, marital status, education level, 
employment status, household income, distance from research center, and overall health 
status.
The survey method was utilized in this study. The discriminant analysis model was 
used to determine if a model existed that significantly increased the researcher’s ability to 
correctly classify volunteers on their participation status in clinical research trials. The
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
overall model was meaningful and successful in correctly classifying 74.6% of the 
original grouped cases.
The strongest findings suggest that African Americans are likely to participate in 
future clinical trials based on their knowledge and perceptions of clinical research trials. 
Principal Investigators and research teams which focus on African Americans in clinical 
research trials should therefore place an increased emphasis on strategic planning that 
involves participants representative of the study population. To yield results, the plan 
should be tailored to African Americans, presented as a credible study, designed to 
reflect trust in the medical care team, and implemented through a continuous educational 
process.
xii
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CHAPTER 1 
INTRODUCTION
Previous abusive clinical trials have caused several obstacles in recruiting African 
Americans for clinical trials today. These past experiences, including those without 
written protocols and uninformed consent, have left nothing but doubt, fear, and mistrust 
among African Americans. The basic trust that African Americans have for physician 
researchers, United States government doctors, United States government-sponsored 
research, and biomedical research in general has been seriously, although not irrevocably, 
breached (Thomas, Pinto, Roach, & Vaughn, 1994a). Modem clinical trials are designed 
and monitored to safeguard against this type of abuse, however, the past effects of 
government-sponsored racism do not dissipate quickly (Thomas et al„ 1994a). For this 
reason, many obstacles of the past hinder the successful recruitment of African 
Americans into clinical trials.
Some of the major obstacles experienced in the past by African Americans include 
the Tuskegee Study of Untreated Syphilis. This study involved over 400 African 
American farmers and was conducted by the United States Public Health Service from 
1932 until 1972 (Jones, 1993). In this study African American men, with a diagnosis of 
syphilis, were given no specific antisyphilitic treatment for 40 years in order to observe 
the natural history of this infectious disease in a large cohort (Thomas et al.). Although 
this study concluded approximately 28 years ago, it is still very prevalent in the minds of 
African Americans today. The neglect and abuse of untreated syphilis for 40 years is a 
hard pill to swallow, then and now. If the United States government betrayed the trust 
of African Americans over 40 years ago, what about today?
1
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Another obstacle from the past that deters African Americans from participation 
in clinical trials occurred between 1845 and 1849 when J. Marion Sims, known as the 
Father of American Gynecology, performed 42 operative procedures on African 
American slave women in Montgomery, Alabama in search of a surgical cure for vesico­
vaginal fistulas (Sims, 1852). Each of the three slave women underwent up to thirty 
painful operations without the benefit of anesthetics. Postoperative medication consisted 
of opium at least twice in 24 hours (Allen, 1994). Consequently, these women were 
eventually made drug addicts as a result of high doses of opium.
Other obstacles using vulnerable populations, or those who have insufficient 
power, intelligence, resources, strength or other needed attributes to protect their own 
interests through negotiations for informed consent (Levine, 1986) include gynecologic 
and reproductive research that continued beyond the 19th century (Allen, 1994).
Between 1957 and 1958 Armand J. Pereyra, M.D., developed his needle urethropexy 
procedure on inmates at the California Penal Institute for Women. The published report 
presented results of procedures performed on 31 inmates (Pereyra, 1959). The San 
Antonio Contraceptive Study involved poor Mexican-American women enrolled in a 
randomized, placebo-controlled, double-blind clinical trial designed to investigate the 
side effects of oral contraceptives (Levine, 1986). The women thought they were 
receiving an active contraceptive; none were informed they would be receiving a placebo 
(sugar pill). Because the trial involved a cross-over design, all participants received a 
placebo for some part o f the trial. As a result, 11 of the 76 participants became pregnant 
during the course o f the trial, 10 while on placebo (Levine, 1986).
2
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It is because of studies such as these and especially the Tuskegee Study, that 
recruiting for clinical trials from the African American population is extremely difficult. 
Remarks like: “you are not going to use me as a guinea pig” or, “what are they putting in 
the food” and, “why are African Americans the only ones participating in this study”, are 
just a few of the negative remarks a research recruiter encounters while trying to recruit 
this population. The challenge in recruiting African Americans is even more crucial 
because chronic disease disproportionately affects them and other minority populations 
in the United States (Singh, Kochanek, & MacDorman, 1996). For example, this is 
particularly true with hypertension, where the associated morbidity and mortality are 
greatest among African Americans (Vollmer, Svetkey, Appel, Obarzanek, Reams, 
Kennedy, Aicher, Charleston, Conlin, Evans, Harsha, & Hertert, 1998). The age- 
adjusted prevalence of hypertension in African American adults is 40 percent higher than 
in Caucasian adults (Burt, Whelton, Roccella, Brown, Cutler, & Higgins, 1995). In 
addition, mortality from blood pressure related cardiovascular diseases is 1.9 to 3.6 times 
greater in African American adults aged 25-64 than in similarly aged Caucasian adults 
(Singh etal., 1996).
The demand for proportionate representation of women, especially African 
American women, in clinical trials is relatively recent. In fact, the textbook description 
of a clinical trial calls for “homogeneous populations of patients” (Goodman & Gilman, 
1990). Unfortunately, these homogeneous populations have been mostly white and 
male. As a result, the National Institutes of Health (NIH) established guidelines for the 
inclusion of women and minorities and their sub-populations in its funded research with 
human subjects (Federal Register, 1994).
3
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Federal funding agencies now require that all proposals and applications with 
human subjects must include women and minority groups to improve gender and race 
representation in clinical trials. These requirements specifically target under-represented 
groups that are disproportionately affected by certain diseases (Kris-Etherton, Mustad,
& Lichtenstein, 1999).
Although there have been notable improvements in health status in the United 
States over the past few decades, the picture of improved health status is not as impres­
sive for African Americans and may have worsened in some cases (Braithwaithe and 
Taylor, 1992). In 1985, the Report of the Secretary’s Task Force on Black and Minority 
Health reported the wide disparity in health status between whites and African Ameri­
cans (Unites States Department of Health and Human Services [USDHHS], 1985). The 
report revealed that approximately 80,000 more African Americans than whites die each 
year, and recent estimates indicate that the numbers continue to increase (Green,
Maisiak, Wang, Britt, & Ebeling, 1997). One of the wide disparities in health status 
between whites and African Americans has been linked to factors associated with utiliza­
tion of health services.
Studies addressing the utilization rates of preventive health services by African 
Americans have been conducted in a number of settings (Berkanovic & Telesky, 1985; 
Caplan, 1992; Green et al., 1997; James, Wagner, Strogatz, Beresford, Kleinbaum, 
Williams, Cutchin, & Ibrahim, 1984; Thomas & Quinn, 1991; Williams, Lavizzo- 
Mourey, & Warren, 1994). The conclusions drawn in these studies indicate that there is 
a need for a  better understanding of underutilization of health services, including those 
involving participation of African Americans in clinical research trials.
4
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Purpose of the Study 
The purpose of this study was to gain an understanding of the knowledge, 
attitudes, and beliefs African Americans have that support decisions to either participate 
or not participate in a clinical trial.
Objectives
The following specific objectives were formulated to guide the researcher:
1. To describe African Americans who were potential participants in clinical
research trials on each of the following perceptual and demographic measures:
a. Knowledge of clinical research processes;
b. Perceptions of clinical research purposes and procedures;
c. Advantages and disadvantages for the individual of participation in 
clinical research trials;
d. Characteristics of current and past participation in clinical research trials;
e. Exposure to selected experiences which are preliminary to participation in 
clinical research trials;
f. Perceptions regarding the need for selected changes in preparation for 
participation in clinical research trials; and






Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
vi. Household income,
vii. Distance from research center, and
viii. Overall health status
2. To describe and compare African Americans who have participated in clinical 
research trials and those who have not participated in clinical research trials on 
each of the following perceptual and demographic measures:
a. Knowledge of clinical research processes;
b. Perceptions of clinical research purposes and procedures;
c. Advantages and disadvantages for the individual of participation in 
clinical research trials;
d. Characteristics of current and past participation in clinical research trials;
e. Exposure to selected experiences which are preliminary to participation in
clinical research trials;
f. Perceptions regarding the need for selected changes in preparation for 
participation in clinical research trials; and







vii. Distance from research center, and
6
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
viii. Overall health status.
3. To determine if a model existed that significantly increased the researcher’s
ability to correctly classify volunteers on their participation status in clinical
research trials from the following perceptual and demographic measures:
a. Knowledge of clinical research processes;
b. Perceptions of clinical research purposes and procedures;
c. Advantages and disadvantages for the individual of participation in 
clinical research trials;
d. Characteristics of current and past participation in clinical research trials;
e. Exposure to selected experiences which are preliminary to participation in
clinical research trials;
f. Perceptions regarding the need for selected changes in preparation for 
participation in clinical research trials; and







vii. Distance from research center, and
viii. Overall health status.
7
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Significance o f the Study 
The success of a clinical trial is dependent upon the success of recruiting the 
required number of volunteers. To gain an understanding of the knowledge, attitudes, 
and beliefs African Americans have regarding clinical research trials is the first step in 
obtaining useful information that will assist and guide researchers for future recruitment 
of African Americans. The results of this study should further assist researchers in 
strengthening their recruitment efforts and strategies for increased participation of 
African Americans in clinical research trials.
Limitation of the Study 
This study is limited to African Americans who participated and those who did 
not participate in a clinical trial at the Pennington Biomedical Research Center from 
1992-2000. Since age, gender, and marital status are demographic characteristics 
collected on all potential volunteers, the Chi-square statistical test was used to determine 
if the respondents in this study were representative of the total population in the 
Pennington Biomedical Research Center’s database. The Chi-square statistical test was 
significant revealing that the respondents in this study were significantly different on the 
examined characteristics from the total population as defined in the study.
However, it should be noted that even though the respondents in this study were 
different from the population of the study on the examined characteristics, they were in 
fact very similar to respondents in other studies of African American populations. 
Specifically, the respondents had a higher percentage of married individuals than were 
evident in the Pennington Biomedical Research Center’s population, but the percentage 
of married individuals was very similar to the results of the study by (Appel, Vollmer,
8
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Obarzanek, Aicher, Conlin, Kennedy, Charleston, & Reams, 1999). Likewise, the 
percentage of female respondents was higher than male respondents in this study and 
very similar to the results of the study by Corbie-Smith, Thomas, Williams, & Moody- 
Ayers, 1999). The highest percentage of respondents in this study were in the 46-55 age 
group and similar results were found in studies by (Appel et al., 1999; Corbie-Smith, et 
al., 1999; Green et al., 1997).
Definition of Terms
For the purpose and objectives of this study the following terms were operation­
ally defined:
Clinical Trial: A clinical trial is a research study that can be used to answer questions 
about vaccines or new therapies or new ways of using known treatments. Clinical trials 
(also called medical research and research studies) are used to determine whether new 
drugs or treatments are both safe and effective. Carefully conducted clinical trials are the 
fastest and safest way to find treatments that work.
Informed Consent: Informed consent is the process of learning the key facts about a 
clinical trial before deciding whether or not to participate. These facts include:
• Why the research is being done.
• What the researchers want to accomplish.
• What will be done during the trial and for how long.
• What risks are involved in the trial.
• What benefits can be expected from the trial.
• What other treatments are available.
• And, the right to leave the trial at any time.
9
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Nonparticipant: Eligible volunteers who either chose not to participate or were ineligible 
to participate in a clinical trial.
Participant: Eligible volunteers who chose to participate in a clinical trial.
Protocol: All clinical trials are based on a set of rules called a protocol. A protocol 
describes what types of people may participate in the trial; the schedule of tests, proce­
dures, medications, and dosages; and the length of the study. While in a clinical trial, 
participants are seen regularly by the research staff to monitor their health and to deter­
mine the safety and effectiveness of their treatment.
10
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CHAPTER 2 
REVIEW OF RELATED LITERATURE 
The review of related literature is divided into four sections. The first section 
will discuss obstacles to recruiting African Americans in clinical trials. The next section 
will discuss the importance of African American involvement in clinical trials. The third 
section will discuss relevant, related literature. The final section will discuss researcher 
biases that may have an impact on recruiting African Americans in clinical trials.
Obstacles to Recruiting African Americans in Clinical Trials 
Historical Obstacles to Enrollment in Clinical Trials
There are many obstacles to the participation of African Americans in clinical 
trials. Historically, medical research is viewed with suspicion among many African 
Americans, and this creates a major hurdle. In perhaps the best known case of research 
abuse, the United States Public Health Service began enrolling 400 black men, without 
informed consent, into a natural history study of untreated, latent syphilis in 1932 (Allen, 
1994). In 1946, it was reported that the death rate among those with syphilis was twice 
as high as among the controls, yet the U.S. Public Health Service continued the study, 
withholding treatment long after penicillin became available as standard therapy (Allen, 
1994). It was not until the lay press exposed this in early 1970 that the study was inter­
rupted (Jones, 1993). In another natural history study financed by the Army, mentally 
retarded infants and children at the Willowbrook State School were deliberately infected 
with hepatitis (Levine, 1986). In a recent study at the University of California, Los 
Angeles, schizophrenics were reportedly taken off their medication to determine what 
would happen. The “informed consent” offered little detail of possible consequences.
11
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One of the subjects committed suicide after his family tried in vain to have his medication 
reinstated (Allen, 1994). In fact, 32 of 50 patients in the study suffered severe relapses. 
Some authors have expressed concern that racial minorities might be over-represented in 
general in clinical trials (El-Sadr & Capps, 1992). Levine (1986) stated, “The inner-city 
location of many university hospitals is problematic in that it increases the likelihood of 
disproportionate use of racial and ethnic minorities as well as impoverished people as 
research subjects.” Stevenson, 1989 addressed this concern by reviewing the representa­
tion of African Americans in studies published in 1984, 1985, and 1986 in Clinical Phar­
macology and Therapeutics. He found that in the majority of these studies, the propor­
tion of African American participants was less than their proportion in the general 
population.
Traditionally, the recruitment of a patient for a clinical trial involves primarily the 
provision of information regarding the specifics of the trial prior to obtaining informed 
consent. However, for the patient who has no previous conception of a clinical trial, 
successful recruitment requires an extensive educational effort. This education must 
include an explanation of the meaning of a trial, random sampling, the nature of blinding, 
and the concept of a placebo, and a description of the responsibilities of the provider and 
the participant, among other information (El-Sadr & Capps, 1992). It is not until after 
the volunteer has a complete understanding of these issues that the specific protocol can 
be discussed. This is a time-consuming process that requires educational skills, patience, 
and the building of trust. It also requires the availability of creative and appropriate 
educational materials. Often the widely available educational materials are not suitable 
for the patient who has not had an extensive education (El-Sadr & Capps, 1992).
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Poor, often minority, patients have traditionally sought care at their neighbor­
hood institutions. They are reluctant to travel or to accept referral to unfamiliar institu­
tions and providers. Thus, one of the most important barriers to their recruitment has 
been the fact that, until recently, few of the trials were conducted at institutions where 
many of these patients receive their primary care. The ability o f the primary care provid­
er to explain the clinical trial to his or her patient is more likely to overcome mistrust and 
reluctance, and the fact that the patient does not have to travel to another institution to 
participate in a trial may facilitate recruitment ((El-Sadr & Capps, 1992).
Socio-cultural Obstacles to Enrollment in Clinical Trials
The many social needs of minority volunteers often hinder their ability to partici­
pate in clinical trials. These issues are seldom addressed or funded by sponsors of 
clinical trials. Often the primary interests of sponsors are the rapid completion of the 
trial and maximum adherence at minimum cost. Many volunteers are homeless, active 
drug users, and many are women with young children. In addition, volunteers have 
limited income and lack resources for associated transportation, food, and nutritional 
supplements (El-Sadr & Capps, 1992). Thus, successful recruitment and, even more 
important, adherence to protocol visits are dependent on more than just providing the 
study drug. Successful recruitment and volunteer adherence depend on the availability of 
a social worker to provide advice on housing, substance abuse programs, and other 
services. They also depend on providing child care, convenient transportation, and a 
warm meal during visits (El-Sadr & Capps, 1992). The importance o f a participant 
advocate who can track down volunteers and assist them in making protocol related 
visits is critical.
13
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Other prevailing socio-cultural obstacles include racial and ethnic discrimination 
(Blendon, Scheck, Donelan, Hill, Smith, Beatrice, & Altman, 1995; El-Sadr & Capps, 
1992; Freeman, 1989; Hutchinson, 1992; Swanson & Ward, 1995; Thomas et al., 1994a; 
Thomas, Quinn, Billingsley, & Caldwell, 1994b) and cultural beliefs about specific 
diseases or illness in general (Ballard, Nash, Raiford, & Harrell, 1993; Bennett, 1993; 
Freeman, 1993; Groce & Zola, 1993; Kaluzny, Brawley, Garson-Angert, Shaw, Godley, 
Wamecke et al., 1993; and Swanson & Ward, 1995). There is widespread fear and 
mistrust of the medical care system among various minority populations as a result of 
indifference and disrespect exhibited by some health care professionals toward those who 
are socio-economically disadvantaged (Freeman, 1993; Haynes & Bernard, 1992; 
Kaluzny et al., 1993; McCabe, Varricchio, & Padberg, 1994; Swanson & Ward, 1995; & 
Wray, 1992). Minorities have been devalued by the health care system, and their 
illnesses often have been labeled as deviance (Blendon et al. 1995; El-Sadr & Capps, 
1992; Hutchinson, 1992; Swanson & Ward, 1995). In addition, general racial 
discrimination and segregation in our society produce fear and mistrust of federally 
sponsored projects, academic medicine, and clinical research (Nickens, 1990; Swanson 
& Ward, 1995 & Thomas et al., 1994a; Thomas et al., 1994b). Finally, differences in 
health beliefs and health behaviors also influence the potential for clinical trial participa­
tion. For example, some African American, Hispanic, and rural populations are more 
likely to delay seeking medical treatment and to under utilize preventive care, resulting in 
higher levels of presentation with later stage cancers (Durant, Ashworth, Newman, 
McGill, Raban*& Baranowski, 1992; Freeman, 1993; Swanson & Ward, 1995; Wray, 
1992).
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Economic Obstacles to Enrollment in Clinical Trials
The impact of socioeconomic status on health and use of medical services is 
receiving increased attention (Dutton & Levine, 1989; Epstein, Stem, Tognelti, Begg, 
Hartley, Cumella, & Ayanian, 1988; Feinstein, 1993; Rask, Williams, Parker, & 
McNagny; Adler, Boyce, Chesney, Folkman, & Syme, 1993). Recent studies have 
shown that insurance coverage alone does not guarantee use of timely and appropriate 
medical care (Dutton, 1978; Pappas, Queen, Hadden, & Fisher, 1993; Riportella-Muller, 
Richardson, Luchok, Donat, & Selby-Harrington, 1993; S t Peter, Newacheck, &
Halfon, 1992; Savitz & Ricketts, 1993). Other economic obstacles faced by indigent 
volunteers include out-of-pocket medical expenses; lack of sick leave, child care costs, 
and lack of transportation (Kiefe & Harrison, 1993; Riportella-Muller et al., 1993; Savitz 
& Ricketts, 1993). Health care system and organizational barriers that are particularly 
likely to affect minority populations include availability of public health care facilities, 
lack of providers for Medicaid, and geographic accessibility of ambulatory care 
(Riportella-Muller et al., 1993; Savitz & Ricketts, 1993; Yudkowsky, Cartland, & Flint, 
1990).
Additional specific or enabling factors can include language barriers, educational 
deficits, health beliefs, and dysfunctional social or home environments (Feinstein, 1993). 
Minority populations are also more likely to experience adverse environmental and social 
conditions, such as crime and violence, that hamper their ability to modify health-dam­
aging behaviors and obtain adequate care (Adler et al., 1993; Dutton & Levine, 1989; 
Feinstein, 1993). If these economic, structural, and cultural factors are significant barri­
ers to medical care, they may result in delays in seeking care and adverse health
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outcomes independent of health insurance status (Shea, Miara, Ehrlich, Field, & Francis, 
1992; Weissman, Stem, Fielding, & Epstein, 1991).
The overwhelming economic obstacles to the participation of many minority 
populations in clinical trials is lack of access to health care in general (Blendon et al., 
1995; DuRant et al., 1992; Elks, 1993; Elks, Short, Cornelius, & Goldstone, 1990; 
Freeman, 1993; Kindig & Yan, 1993; Murdaugh, 1990; Reis, Sherman, & Macon, 1989; 
Swanson & Ward, 1995; Walker, Lucas, & Crespo, 1994; Wray, 1992). Lack of health 
insurance is a critical factor that limits access to health care among low-income, minority 
populations (Short et al., 1990; Swanson & Ward, 1995). The poor quality o f general 
health services available in some African American and other low-income communities is 
another important factor that limits access to health care, thus to clinical trials (Blendon 
et al., 1989; Freeman, 1989; Kindig & Yan, 1993; Swanson & Ward, 1995, Wray,
1992). There is evidence that rural and elderly minority populations are subsets of 
minorities that have least often been included in clinical trials (Kindig & Yan, 1993; 
Swanson & Ward, 1995; Wray, 1992).
It is very difficult to unravel the effects of poverty on clinical trials participation 
from those issues related to race and ethnicity (Ballard et al., 1993; Blendon et al., 1989; 
Freeman, 1989; Freeman, 1993; Lacey, 1993; Nickens, 1990; Swanson & Ward, 1995; 
Thomas et al., 1994b). It is well recognized that poverty is a leading risk factor for 
cancer and other diseases (Freeman, 1989; Kindig & Yan, 1993; Swanson & Ward,
1995). The effects of poverty are extensive, ranging from dangerous living environments 
to poor nutrition and inadequate housing; to unemployment, financial instability, and
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inability to obtain public assistance; to lack of telephones and transportation (Ballard et 
al.,1993; Blendon et al., 1989; Lacey, 1993; Swanson & Ward, 1995).
Obstacles Inherent in Study Design
Minority health care professionals are raising important issues about restrictive 
exclusion criteria. They indicate that entire segments of the population are effectively 
banned from obtaining the benefits of clinical trials, including improved medical care, 
better quality of life, longer survival, and access to compensation that accompanies some 
studies (Elks, 1993; El-Sadr & Capps, 1992; Jimenez & Jimenez, 1992; Milton- 
Underwood, Sanders, & Davis, 1993; Swanson & Ward, 1995). Differences in drug 
response and in other outcomes across diverse ethnic groups and by sex further prolong 
the problems resulting from limited access to clinical trials among these groups (Crews 
and Bindon, 1991; El-Sadr & Capps, 1992; Merkatz, Temple, Subel, Feiden, & Kessler, 
1993; Milton-Underwood et al., 1993; Swanson & Ward, 1995).
Complexity of forms and procedures also inhibit participation of many popula­
tions (Elks, 1993; Haynes & Bernard, 1992; Kaluzny et al., 1993; McCabe et al., 1994; 
Swanson & Ward, 1995; Freeman, 1993; Wray, 1992;). Forms used to ensure informed 
consent are a good example of this problem, as most of them are well above the reading 
level of some populations, may not explain the benefits of the trial, may not explain that 
care given as routine is not very effective, or may actually induce fear if  they are too 
complex (Elks, 1993; Haynes & Bernard, 1992; Swanson & Ward, 1995).
Importance of African Americans Involvement in Clinical Trials 
Chronic disease disproportionately affects African Americans and other minority 
populations in the United States (Singh et al., 1996) and therefore, the need to enroll
17
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African Americans into clinical trials is necessary to reduce this disparity. It is important 
for African Americans to participate in clinical trials because of the potential to identify 
effective prevention, and treatment strategies for many of the health conditions that 
afflict them. Yet, African Americans and other minorities do not participate in clinical 
trials in numbers proportional to their risk of disease (Thomas et al., 1994a). Since race 
can affect disease severity, progression, and response to drug therapy (Matthews, 1995), 
under-representation of African Americans and other ethnic minorities in clinical trials 
will decrease the ability to generalize study results to minority populations.
More specifically, applicability of findings would be questionable for the various 
racial/ethnic groups as documented by the National Cancer Institute (NCI). For 
example, the severity of the cancer problem among racial/ethnic populations compared 
with that among the general population is such that timely, definitive data are critical to 
improve cancer survival rates and reduce treatment side effects (Pickle, Mason, Neil, 
Hoover, & Fraumeni, 1990; Roberson, 1994). Results from clinical trials would be 
useful to determine the efficacy of treatments for sites where cancer rates are high for the 
various racial/ethnic groups compared with the general population.
For almost all health care problems, morbidity and mortality rates are substan­
tially higher for the ethnic minority group than for the non-minority population 
(Raczynski, 1997). The mortality rates for African Americans in most all age levels for 
both males and females exceed those of whites with some of these rates double or more 
(Raczynski, 1997). While income and other benefits that go along with income are 
factors accounting for excess disease outcomes for African Americans, about one-third 
o f the excess mortality in one analysis was accounted for by risk factors, suggesting a
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greater importance for African Americans across the country lies in learning better 
methods of preventing disease outcomes (Otten, Teutsch, Williamson, & Marks, 1990).
Relevant Related Literature
Clinical trials play a dominant role in clinical oncology today (Devita, Heilman, 
& Rosenberg, 1989). Despite the state-of-the-art cancer treatment, however, there is 
mounting concern that the benefits of this medical and scientific progress is not being 
equitably shared by or distributed to all segments of the U.S. population (Byrd & Clay­
ton, 1992).
The fact that racial/ethnic groups are under-represented in cancer clinical trials is 
supported by a review of literature that showed that very few volunteers, and in most 
cases no racial/ethnic volunteers, are enrolled in clinical trials (Byrd & Clayton, 1992; 
Roberson, 1994). Under-representation was further evident in the Clinical Trials 
Program of the NCI, in which recruitment efforts yielded low volunteer accrual since the 
initiation of the program in 1955 (Meinert & Tonascia, 1986; Roberson, 1994). It was 
not until 1990 that the NCI directed specific attention to the problem of low 
participation of racial/ethnic volunteers. Through its Minority Community Clinical 
Oncology Program, the NCI sought to improve volunteer accruals primarily through 
historically minority colleges and institutions (Byrd & Clayton, 1992).
Under-representation of racial/ethnic volunteers in cancer clinical trials also sur­
faced and became a critical issue during the Congressional Hearings 1992 on the NCI 
Breast Cancer Prevention Trial (BCPT). Among one of the key issues was the failure to 
address the recruitment of adequate numbers of racial/ethnic women for participation in 
the study. Within a  2-year period, fewer than 2% of minority women were enrolled
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(Payne, 1992). No strategic plan was in place to include these women or improve 
accrual rates.
Researchers at the Pennington Biomedical Research Center (Baton Rouge, 
Louisiana) have also experienced several obstacles in recruiting African Americans for 
clinical trials. One of the specific research studies that had major obstacles was known 
as the Estrogen Patch Study for women who were postmenopausal and Type II diabetic. 
The goal was to recruit 70 African American women however, 18 enrolled, and only 15 
(4 Caucasians and 11 African Americans) completed the one-year study. The purpose of 
the study was to determine if risk factors for heart disease could be improved, whether 
or not body composition and fat distribution could be altered, and if the ability of the 
body to deal with the sugar in the blood could be improved using a hormone patch. Half 
of the women received an active hormone patch while the other half received a placebo 
(non-active hormone patch).
Another study that had difficulties in recruiting African Americans was Dietary 
Approaches to Stop Hypertension (DASH). DASH was a national multi-center trial 
sponsored by the National Lung and Blood Institute (Bethesda, Maryland). The study 
was conducted at the Pennington Biomedical Research Center and 4 other Centers:
Duke University (Durham, North Carolina), Brigham and Women’s Hospital (Boston, 
Massachusetts), Johns Hopkins University (Baltimore, Maryland), and Kaiser 
Permanente Coordinating Center (Portland, Oregon). The task for the Pennington 
Center was to recruit 100 percent African Americans while the other centers had goals of 
either 50 percent other/50 percent minority or 60 percent other/40 percent minority. 
DASH was an eleven-week feeding study that required volunteers to eat the dinner meal
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at the Center and all other meals (breakfast, lunch, and snacks) packed to go. In 
addition, volunteers earned $600 after completing the eleven-week study.
Although hypertension is a disease that disproportionately affects African 
Americans, the obstacles faced in recruiting them for the DASH trial was a challenge. 
Some of the challenges included rescheduling appointments, changed their minds, or they 
did not show up for original or rescheduled appointments. Other challenges included 
what they were saying about the trial such as: “why are you only recruiting African 
Americans”, or “what are they putting in the food”, or “ I do not eat my food cooked 
like that”, and finally, “what are they doing with my blood”. To try and alleviate some of 
these obstacles, strategies must be established to gain trust among African Americans. 
One way to gain trust was to participate in the clinical trial so that potential participants 
would feel more at ease. However, gaining trust by participating in the trial may not be 
enough especially when the majority of other staff members (Principal Investigator, Co- 
Principal Investigators, Medical Director, Clinic Supervisor, Nurses, Dietitians, and 
Research Associates) having direct contact with this targeted group were non-African 
American. Although the goal was to enroll 100 percent African Americans in the DASH 
study, permission was granted to enroll 10 Caucasians and Other to complete the trial 
with the required number of participants.
Other studies with obstacles in recruiting African Americans at the Pennington 
Center included: DASH2 (Fourteen-week feeding study), Diabetes Prevention Program 
(Six-year on-going intervention/drug trial), and Healthy Transitions (Four-year longitudi­
nal study of perimenopausal women). The goal of the Healthy Transitions study for 
example, was to recruit SO percent African American and SO percent Caucasian women
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and observe them before, during, and after menopause. However, out of 183 women 
recruited, only 42 or 23 percent were African American.
Currently, there are two clinical trials at the Pennington Biomedical Research 
Center requiring 100 percent African American participants. The first study, Maternity 
Obesity Management Study (MOMS) is a study for females age 16 and over who gained
v '
and retained an excess of 25 pounds or more of weight after delivery of their baby, and 
had no complications during pregnancy such as gestational diabetes. The recruitment 
goal of the study was to have 56 volunteers enrolled by March 2001. As of February 
2001 all 6 volunteers previously enrolled had dropped out of the study. Despite many 
recruitment efforts such as: TV appearances, radio (live talk show), flyers and luncheons 
taken to physician offices, flyers in pediatric clinics, day care centers, beauty shops, and 
several other medical and non-medical entities, African American women who had 
scheduled appointments did not show up and/or rescheduled appointments, did not show 
up. The principal investigator therefore, requested permission from NIH and it was 
granted, to extend recruitment to all females meeting the study criteria.
The second study currendy being recruited is the Health Improvement Program- 
for Teens (HIP-Teens). This study is for overweight African American girls age 11-15 
with at least one overweight parent. The goal is to recruit 60 families using the Internet 
to interact with both groups to prevent weight loss through either behavioral change or 
nutritional education. There are 12 families currently enrolled with another 48 required 
to meet the recruitment goal of the study.
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Researcher Biases
Some of the obstacles that result from researcher bias are frequently viewed by 
the researchers as obstacles that are due to the individuals or populations to be recruited 
into clinical trials (DuRant et al., 1992; Freeman, 1993; Haynes & Bernard, 1992; 
Jimenez & Jimenez, 1992; Nelson, 1994; Swanson & Ward, 1995; Wermeling & Selwitz,
1993). The biases of researchers and clinical investigators include failure to 
accommodate cultural and economic diversity of potential study participants, failure to 
recognize that restrictive studies do not fully assess safety and efficacy of new treatments 
or preventive interventions for all populations, claims that statistical power will be 
reduced if women and minorities are included, inaccurate beliefs that certain populations 
are not at risk for specific conditions or illnesses, and failure to establish research clinics 
in minority institutions (DuRant et al., 1992; Freeman, 1993; Jimenez and Jimenez, 1992; 
Lacey, 1993; Swanson & Ward, 1995; Wermeling & Selwitz, 1993).
Finally, one of the most common excuses for not including minorities in preven­
tion and treatment trials is that they are “hard to reach” (Lacey, 1993; Swanson & Ward, 
1995). This is the typical example of researcher insensitivity and discrimination: the 
population is defined as difficult and problematic, conveniently ignoring the fact that it is 
the life conditions of these populations that are problematic; not the people (Swanson & 
Ward, 1995).
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CHAPTER 3 
METHODS AND PROCEDURES 
The purpose of this chapter was to describe the procedures used in the study, 
including sampling, data collection, and data analysis. These procedures were used to 
address the purpose of the study: to gain an understanding of the knowledge, attitudes, 
and beliefs African Americans have that support decisions to either participate or not 
participate in a clinical trial.
Population and Sample 
The target population was defined as all African Americans age 18 and older who 
were potential participants in a clinical trial. The accessible population were all African 
Americans in the Pennington Biomedical Research Center Database from 1992-2000. 
The frame of the accessible population was established as those who were currently 
enrolled at the time of the study, previously participated, and those who did not 
participate in a clinical trial. The sample consisted of 100% of the defined accessible 
population frame.
Instrument
A modified version of the questionnaire (Appendix B) “Perceptions of Participation in 
Clinical Research” (McLean & Jensen, 1998) was utilized in conducting this study. 
Permission to modify and utilize the original questionnaire was granted in writing by the 
authors (Appendix C). The original questionnaire was modified due to the relevance of 
questions applicable to African Americans, length of the instrument, and the approximate 
time it would take to complete.
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The modified version of the questionnaire consisted of 8 pages, 58 questions, and 
7 sections. The first section consisted of 7 items to measure knowledge of clinical 
research processes, section two consisted of 8 items to measure perceptions of clinical 
research purposes and procedures, section three contained two parts: advantages (8 
items and other) and disadvantages (6 items and other) for the individual of participation 
in clinical research trials, section four consisted of 6 questions to examine the 
characteristics of current and past participation in clinical research trials, section five 
contained 4 items to determine the exposure to selected experiences which are 
preliminary to participation in clinical research trials, section six contained 6 choices and 
other to measure the perceptions regarding the need for selected changes in preparation 
for participation in clinical research trials, and section seven consisted of 8 selected 
personal demographic characteristics including gender, age, marital status, education 
level, employment status, household income, distance from research center, and overall 
health status. Participants were assured of confidentiality and that there were no right or 
wrong answers in completing the survey instrument. The questionnaire began with the 
definition of a clinical trial and instructions for completion.
The original instrument from which the study instrument was adapted had been 
validated by expert panels. Because modifications were made for the purpose of the 
current study, a validity assessment for the study instrument was needed. Face validity 
of the instrument was established through a review by three professors at Louisiana State 
University (three from the School of Human Resource Education and Workforce 
Development, two active and one emeritus), and one professor from the Biostatistics 
Department, Pennington Biomedical Research Center.
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Reliability of the instrument was assessed in September 2000 by conducting a 
field test with African Americans who were not a part of the study, but similar to those 
in the target population. The purpose of the field test was to determine what kind of 
feedback to expect from African Americans who would respond to the questionnaire in 
this study. Based on a favorable response from African Americans in the field test, the 
researcher concluded the questionnaire favorable for potential respondents in this study. 
Reliability of the scaled response sections of the instrument was estimated using 
Cronbach’s Alpha internal consistency coefficient. This included sections I, II, III, and 
VI of the modified questionnaire.
The Cronbach’s Alpha internal consistency coefficients were as follows:
Scale Number of items Cronbach’s Alpha
Section I - Knowledge 7 .78
Section II - Perceptions 8 .81
Section m  - Part I Advantages 8 .83
Section III - Part II Disadvantages 6 .85
Section VI - Ideas/Suggestions 6 .83
Data Collection
The questionnaire was mailed to 3302 African American adults (770 participants 
and 2532 nonparticipants) who were potential participants in a clinical trial at the 
Pennington Biomedical Research Center during the years of 1992-2000. A total of 117 
questionnaires (49 participants and 68 nonparticipants) were returned undeliverable. 
Since the addresses in the database for participants and nonparticipants were up to 8
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years past, the researcher believed that many participants and nonparticipants did not 
respond because they had moved and the forwarding order had expired.
Labels were printed and addressed to each participant and nonparticipant in the 
Pennington Biomedical Research Center database from 1992-2000. Questionnaires were 
mailed along with a self-addressed stamped envelope. A letter of introduction (Appen­
dix A) accompanied the questionnaire. Along with instructions and guidelines, the letter 
stressed the importance of completing the survey. The questionnaires were coded by 
seven digits of non-repeated random numbers to allow follow-up for unretumed 
questionnaires. Participants were asked to return questionnaires within two weeks after 
receiving.
After the third week, questionnaires began to decrease in numbers and 
immediately follow-up began and continued for one month and nine days. Follow-up 
included calling and reminding potential participants that it was not too late to return 
questionnaires. Some questionnaires came back with a new address and they were resent 
locally as well as to those who had moved out-of-state. Some respondents completed 
and dropped-off questionnaires to the researcher at the Pennington Biomedical Research 
Center. A total o f386 (158 participants or 21 percent, and 228 nonparticipants or 9 
percent) responded to the questionnaire.
Data Analysis
Data collected in this study was analyzed using the following procedures for each 
respective study objective:
• Objective one was to describe African Americans who were potential
participants in clinical research trials on (a) knowledge of clinical research
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processes, (b) perceptions of clinical research purposes and procedures, 
(c) advantages and disadvantages for the individual of participation in 
clinical research trials, (d) characteristics of current and past participation 
in clinical research trials, (e) exposure to selected experiences which are 
preliminary to participation in clinical research trials, (f) perceptions 
regarding the need for selected changes in preparation for participation in 
clinical research trials, and (g) selected personal demographic characteris­
tics to include: gender, age, marital status, education level, employment 
status, household income, distance from research center, and overall 
health status.
The researcher used descriptive statistics (frequency, percentage, mean, standard 
deviation, range) and factor analysis for objective one. Sections one, two, three, and six 
of the instrument was collected as continuous (interval data). Sections four, five, and 
seven was collected as categorical (nominal and ordinal data).
• Objective two was to describe and compare African Americans who have 
participated in clinical research trials and those who have not participated 
in clinical research trials on each of the items in objective one listed 
above. An alpha level of .05 was used to determine significance through­
out the study.
To describe the groups, the researcher used descriptive statistics (mean, standard 
deviation) and factor analysis for objective two. To compare the groups, the researcher 
used the independent samples t-test procedure and Chi-square statistical techniques as 
applicable.
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• Objective three was to determine if a model existed that significandy
increased the researcher's ability to correcdy classify volunteers on their 
participation status in clinical research trials on each of the items in 
objective one listed above.
The researcher used discriminant analysis to accomplish objective three.
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CHAPTER 4 
FINDINGS 
Knowledge of Clinical Research Processes 
Findings presented in this chapter are organized by objectives of the study. The 
first objective was to describe African Americans who were potential participants in clin­
ical research trials on their level of knowledge of clinical research processes. To 
measure the level of knowledge of clinical research processes, a seven item scale was 
used. The response scale utilized was a five-point Likert-type scale with values ranging 
from 1 = “Strongly Disagree” to 5 = “Strongly Agree”. The middle point (3) on the 
scale did allow the respondents the option of an “Unsure” answer. To aid in the 
interpretation of this data, the researcher established an interpretive scale based on the 
responses available to the study participants. This scale had descriptions and 
corresponding values as follows: 1.00 to 1.50 = “Strongly Disagree;” 1.51 to 2.50 = 
“Disagree;” 2.51 to 3.49 = “Unsure;” 3.50 to 4.49 = “Agree;” and 4.50 to 5.00 = 
“Strongly Agree.”
When the data from the responses to the seven statements on the scale were 
examined, the statement with which the respondents most strongly agreed was, 
“Volunteers can refuse to participate in a clinical trial” (mean = 4.61, SD = .67). This 
statement was classified using the interpretive scale as “Strongly Agree”. The statement 
with which participants least agreed was, “Volunteers usually receive a cash stipend for 
participation in a clinical trial” (mean = 4.00, SD = .89). The mean response to this 
statement was classified in the “Agree” category. Overall, one statement in this scale
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was classified as “Strongly Agree,” and six statements were classified as “Agree” (see 
Table 1).
Table 1
Level o f Knowledge of Clinical Research Trials of Potential African American 
Participants
Item n Mean* SD Classification1
Volunteers can refuse 
to participate in a 
clinical trial.
385c 4.61 .67 Strongly Agree
Clinical trials are 
needed to study the 
effects of treatments.
385c 4.46 .68 Agree
Volunteers can change 
their mind at any time 
and withdraw from a 
clinical trial.
384d 4.20 .98 Agree
Volunteers receive 
information needed to 
decide whether they 






CO 4.10 1.03 Agree
Volunteers are told 
about the possible risks 
and benefits of taking 
part in a clinical trial.
386 4.08 .98 Agree
Volunteers are made 
aware of any possible 
complications or side 




CO 4.02 1.01 Agree
(Table continues)
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Volunteers usually
o00 4.00 .89 Agree
receive a cash stipend
for participation in a
clinical trial.
“Response scale: 1 = strongly disagree; 2 = disagree; 3 = unsure, 4 = agree; 5 = strongly 
agree.
'’Mean responses were classified using the following descriptors for specified value 
ranges: 1.00-1.50 = strongly disagree; 1.51-2.50 = disagree; 2.51-3.49 = unsure; 3.50-
4.49 = agree; 4.50-5.00 = strongly agree. 
cOne respondent did not answer this item. 
dTwo respondents did not answer this item.
To further summarize the information regarding level of knowledge of clinical 
research processes, the researcher used factor analysis to determine if underlying con­
structs could be identified in the scale. The analysis procedure used was principal com­
ponents analysis with a varimax rotation method.
The first step in conducting the factor analysis was to determine the optimum 
number of factors to be extracted from the scale. Using a combination of the latent root 
criterion, and the scree test criterion, the number of factors to be extracted was deter­
mined to be two. The results of the factor analysis including the factor, it’s label based 
on the content of the items included in the factor, the percentage of variance explained 
by each factor, and factor loadings for each of the statements in each of the factors is 
presented in Table 2. The two sub-scales were labeled by the researcher as “Information 
Provided,” and “Awareness.” The first factor identified in the scale was information 
provided that related to knowledge of clinical research processes. Items in this factor 
included, “Volunteers are told about the possible risks and benefits of taking part in a 
clinical trial”, “Volunteers are made aware of any possible complications or side effects 
o f taking part in a clinical trial”, “Volunteers receive information needed to decide
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whether they want to take part in a clinical trial," and “Volunteers usually receive a cash 
stipend for participation in a clinical trial." The factor loadings ranged from a high of .90 
to a low of .57 and explained 35.8 percent of the overall variance in the scale.
The second factor explained an additional 24.7 percent of the overall scale vari­
ance and included items related to awareness of clinical research processes. Items in this 
factor included, “Volunteers can change their mind at any time and withdraw from a 
clinical trial”, “Volunteers can refuse to participate in a clinical trial,” and “Clinical trials 
are needed to study the effects of treatments." The factor loadings ranged from a high of 
.83 to .48.
Table 2




(35.8% of variance 
explained)
Factor I Factor 2
Volunteers are told about 
the possible risks and 
bene- fits of taking part in 
a clinical trial.
.90 .08
Volunteers are made 
aware of any possible 
complications or side 




mation needed to decide 
whether they want to take 
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Volunteers usually receive 
a cash stipend for 




(24.7% of variance 
explained)
Factor 1 Factor 2
Volunteers can change 
their mind at any time and 
withdraw from a clinical 
trial.
.02 .83
Volunteers can refuse to 
participate in a clinical 
trial.
.25 .77
Clinical trials are needed to 
study the effects of treat­
ments.
.40 .48
After the two sub-scales and items to be included in each were identified, the 
researcher computed scale scores for each of the two identified sub-scales. These sub­
scale scores were identified as the mean of the items included in each of the respective 
factors. For the first scale labeled “Information Provided,” the individual subject mean 
scores ranged from a low of 4.00 to a high of 4.10 with an overall mean of 4.05 (SD = 
.76). Using the interpretive scale, this scale received an overall rating classified as 
“Agree.” The second scale was “Awareness,” and had individual subject means that 
ranged from 4.20 to 4.61. The overall mean score was 4.42 (SD = .58) which was 
classified in the “Agree” category. When the sub-scale scores were examined, the factor 
which received the highest mean score was the “Awareness” sub-scale (mean = 4.42, SD 
= .58) (see Table 3).
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Table 3
Knowledge of Clinical Research Trials Sub-Scale Scores of Potential African American 
Participants
Sub-Scale Items Mean* SD Classification6 Range
Awareness 3 4.42 .58 Agree 4.20-4.61
Information
Provided
4 4.05 .76 Agree 4.00-4.10
“Response scale: 1 = strongly disagree; 2 = disagree; 3 = unsure; 4 = agree; and 5 = 
strongly agree.
bMean responses were classified using the following descriptors for specified value 
ranges: 1.00-1.50 = strongly disagree; 1.51-2.50 = disagree; 2.51-3.49 = unsure; 3.50-
4.49 = agree; 4.50-5.00 = strongly agree.
Perceptions of Clinical Research Purposes and Procedures 
Objective (lb) was to describe African Americans who were potential 
participants in clinical research trials on their perception of clinical research purposes and 
procedures. To measure the perception of clinical research purposes and procedures, an 
eight item scale was used. The response scale utilized was a five-point Likert-type scale 
with values ranging from I = “Strongly Disagree” to 5 = “Strongly Agree.” The middle 
point (3) on the scale did allow the respondents the option of an “Unsure” answer. To 
aid in the interpretation of this data, the researcher established an interpretive scale based 
on the responses available to the study participants. This scale had descriptions and 
corresponding values as follows: 1.00 to 1.50 = “Strongly Disagree,” 1.51 to 2.50 = 
“Disagree,” 2.51 to 3.49 = “Unsure,” 3.50 to 4.49 = “Agree,” and 4.50 to 5.00 = 
“Strongly Agree.”
When the data from the responses to the eight items on the scale were examined, 
the statement with which the participants most strongly agreed was, “Participation in a
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clinical trial can help future generations’* (mean = 4.46, SD = .65). This statement was 
classified using the interpretive scale as “Agree.” The statement with which participants 
least agreed was, “Participation in a clinical trial can delay a disease” (mean = 3.19, SD = 
1.15). The mean response to this statement was classified in the “Unsure” category. 
Overall, six items were classified as “Agree,” and two items were classified as “Unsure.” 
Table 4
Perception of Clinical Research Trial Purposes and Procedures of Potential African 
American Participants
Item n Mean8 SD Classificationb
Participation in a 
clinical trial can help 
future generations.
386 4.46 .65 Agree
Clinical trials are a 
necessary way to learn 
about treatments.
385c 4.39 .77 Agree
The information in the 
consent form is impor­
tant to help volunteers 
decide about participa­
tion in a clinical trial.
386 4.26 .81 Agree
It is important for 
people to take part in 
clinical trials.
386 4.24 .84 Agree
Participation in a clini­
cal trial can help me and 
my family.
386 4.21 .80 Agree
Blood work is 
necessary in a clinical 
trial.
386 4.10 .93 Agree
(Table continues)
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Participation in a clini­
cal trial can prevent a 
disease.
386 3.24 1.17 Unsure
Participation in a clini­
cal trial can delay a 
disease.
t>tnoo 3.19 1.15 Unsure
“Response scale: 1 = strongly disagree; 2 = disagree; 3 = unsure, 4 = agree; 5 = strongly 
agree.
"Mean responses were classified using the following descriptors for specified value 
ranges: 1.00-1.50 = strongly disagree; 1.51-2.50 = disagree; 2.51-3.49 = unsure; 3.50-
4.49 — agree; 4.50-5.00 = strongly agree. 
cOne respondent did not answer this item.
To further summarize the information regarding level of perception of clinical 
research purposes and procedures, the researcher used factor analysis to determine if 
underlying constructs could be identified in the scale. The analysis procedure used was 
principal component analysis with a varimax rotation method.
The first step in conducting the factor analysis was to determine the optimum 
number of factors to be extracted from the scale. Using a combination of the latent root 
criterion, and the scree test criterion, the number of factors to be extracted was deter­
mined to be two. The results of the factor analysis including the factor, it’s label based 
on the content of the items included in the factor, the percentage of variance explained 
by each factor, and factor loadings for each of the statements in each of the factors is 
presented in Table 5. The two sub-scales were labeled by the researcher as “Participa­
tion Benefits,” and “Prevention.” The first factor identified in the scale related to per­
ceived benefits as a result of participation in clinical research trials. Items in this factor 
included, “Participation in a clinical trial can help future generations,” “Participation in a 
clinical trial can help me and my family”, “It is important for people to take part in clini-
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cal trials”, “Clinical trials are a necessary way to learn about treatments,” “The informa­
tion in the consent form is important to help volunteers decide about participation in a 
clinical trial”, and “Blood work is necessary in a clinical trial.” The factor loadings 
ranged from a high of .83 to a low of .54 and explained 41.4 percent of the overall 
variance in the scale.
The second factor explained an additional 23.6 percent of the overall scale vari­
ance and included items related to prevention as a result of participation in clinical 
research trials. Items in this factor included, “Participation in a clinical trial can delay a 
disease”, and “Participation in a clinical trial can prevent a disease.” The factor loadings 
ranged from a high of .93 to .91.
Table 5
Factor Analysis of Perception of Clinical Research Trial Purposes and Procedures of 
Potential African American Participants
Factor-Participation 
Benefits 
(41.4% of variance 
explained)
Factor 1 Factor 2
Participation in a clinical 
trial can help future 
genera-tions.
.83 .10
Participation in a clinical 
trial can help me and my 
family.
.79 .26
It is important for people 
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Clinical trials are a neces­
sary way to learn about 
treatments.
.77 .06
The information in the 
consent form is important 
to help volunteers decide 
about participation in a 
clinical trial.
.67 .08




(23.6% of variance 
explained)
Factor 1 Factor 2
Participation in a clinical 
trial can delay a disease.
.11 .93
Participation in a clinical 
trial can prevent a disease.
.15 .91
After the two sub-scales and items to be included in each were identified, the 
researcher computed scale scores for each of the two identified sub-scales. These sub­
scale scores were identified as the mean of the items included in each of the respective 
factors. For the first scale labeled “Participation Benefits,” the individual subject mean 
scores ranged from a low of 4.09 to a high of 4.46 with an overall mean of 4.28, (SD = 
.60). Using the interpretive scale, this scale received an overall rating classified as 
“Agree.” The second scale was “Prevention,” and had individual subject means that 
ranged from 3.19 to 3.24. The overall mean score was 3.22 (SD -  1.09) which was 
classified in the “Unsure” category. When the sub-scale scores were examined, the 
factor which received the highest mean score was the “Participation Benefits” sub-scale 
(mean = 4.28, SD = .60) (see Table 6).
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Table 6
Perception of Clinical Research Trial Purposes and Procedures Sub-Scale Scores of 
Potential A fr ic a n  American Participants
Sub-Scale Items Mean® SD Classification1 Range
Participation
Benefits
6 4.28 .60 Agree 4.09-4.46
Prevention 2 3.22 1.09 Unsure 3.19-3.24
‘Response scale: 1 = strongly disagree; 2 = disagree; 3 = unsure; 4 = agree; and 5 = 
strongly agree.
bMean responses were classified using the following descriptors for specified value 
ranges: 1.00-1.50 = strongly disagree; 1.51-2.50 = disagree; 2.51-3.49 = unsure; 3.50-
4.49 = agree; 4.50-5.00 = strongly agree.
Advantages for the Individual of Participation in Clinical Research Trials 
Objective (lc)was to describe African Americans who were potential participants 
in clinical research trials on perceived advantages for the individual of participation in 
clinical research trials. To measure the perceived advantages for the individual of 
participation in clinical research trials, an eight item scale was used. The response scale 
utilized was a five-point Likert-type scale with values ranging from 1 = “Strongly Dis­
agree” to 5 = “Strongly Agree.” The middle point (3) on the scale did allow the respon­
dents the option of an “Unsure” answer. To aid in the interpretation of this data, the 
researcher established an interpretive scale based on the responses available to the study 
participants. This scale had descriptions and corresponding values as follows: 1.00 to
1.50 = “Strongly Disagree;” 1.51 to 2.50 = “Disagree;” 2.51 to 3.49 = “Unsure;” 3.50 to
4.49 = “Agree;” and 4.50 to 5.00 = “Strongly Agree.”
When the data from the responses to the eight items on the scale were examined, 
the statement with which the participants most strongly agreed was, “Doing something
40
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
that will help others” (mean = 4.42, SD = .61). This statement was classified using the 
interpretive scale as “Agree.” The statement with which participants least agreed was, 
“Getting free medications” (mean = 3.53, SD = 1.04). The mean response to this state­
ment was classified in the “Agree” category. Overall, all eight items were classified in 
the “Agree” category as shown in Table 7.
Table 7
Perceived Advantages of Participation in Clinical Research Trials of Potential African
Item n Mean* SD Classification6
Doing something that 
will help others.
386 4.42 .61 Agree
Doing something 
positive for self.
383e 4.21 .82 Agree
Getting better care and 
follow-up (for example, 
with laboratory tests).
383c 4.20 .83 Agree
Receiving the newest 
treatment.
00 3.93 .86 Agree
Helping to prevent a 
disease.
385“ 3.73 1.00 Agree
Getting a cash stipend. 384f 3.73 1.01 Agree
Helping to delay a 
disease.
386 3.55 1.03 Agree
Getting free medication. 384f 3.53 1.04 Agree
“Response scale: 1 = strongly disagree; 2 = disagree; 3 = unsure, 4 = agree; 5 = strongly 
agree.
‘’Mean responses were classified using the following descriptors for specified value 
ranges: 1.00-1.50 = strongly disagree; 1.51-2.50 = disagree; 2.51-3.49 = unsure; 3.50-
4.49 = agree; 4.50-5.00 = strongly agree.
Three respondents did not answer this item. 
dFour respondents did not answer this item.
“One respondent did not answer this item.
Two respondents did not answer this item.
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To further summarize the information regarding perceived advantages for the 
individual of participation in clinical research trials, the researcher used factor analysis to 
determine if underlying constructs could be identified in the scale. The analysis 
procedure used was principal components analysis with a varimax rotation method.
The first step in conducting the factor analysis was to determine the optimum 
number of factors to be extracted from the scale. Using a combination of the latent root 
criterion, the a ' priori criterion, and the scree test criterion, the number of factors to be 
extracted was determined to be one. The results of the factor analysis including the fac­
tor, it’s label based on the content of the items included in the factor, the percentage of 
varianceexplained by each factor, and factor loadings for each of the items in the factor 
is presented in Table 8. Since only one factor was extracted, the varimax rotation 
method was not applicable. The sub-scale was labeled by the researcher as “Primary 
Benefits.” The only factor identified in the scale related to the primary benefits of 
participation in clinical research trials. Items in this factor included, “Getting better care 
and follow-up (for example, with laboratory tests)”, “Doing something positive for self,” 
“Receiving the newest treatment”, “Doing something that will help others”, “Helping to 
delay a disease”, “Helping to prevent a disease”, “Getting free medications”, and 
“Getting a cash stipend.” The factor loadings ranged from a high of .79 to a low of .58 
and explained 47.4 percent of the overall variance in the scale (see Table 8).
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Table 8
Factor Analysis of Perceived Advantages of Participation in Clinical Research Trials of 
Potential African American Participants
Factor- Primary Benefits 
(explained 47.4% of variance)
Factor
Getting better care and follow-up (for 
example, with laboratory tests).
.79
Doing something positive for self. .77
Receiving the newest treatment. .70
Doing something that will help others. .70
Helping to delay a disease. .68
Helping to prevent a disease. .65
Getting free medications. .60
Getting a cash stipend. .58
Since all the items loaded on one factor, the researcher computed an advantage 
scale score labeled as “Primary Benefits.” This scale score was identified as the mean of 
the items included in the factor. The “Primary Benefits” scale had individual subject 
mean scores that ranged from a low of 3.53 to a high of 4.43 with an overall mean of 
3.91 (SD = .61). Using the interpretive scale, this scale received an overall rating classi­
fied as “Agree.
In addition to the eight specified advantages, respondents were provided the 
opportunity to indicate an “Other” perceived advantage. If they did so, they were also 
asked to specify what this “Other” advantage was. The respondents’ overall list of 
“Other” advantages to participation in clinical research trials were combined into the 
categories: participants (see Appendix D, question 24) and nonparticipants (see Appen-
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(fix E, question 24). There were nine respondents in the participant category that 
specified “Leam about medicine and body,” and three specified “Meeting others” as 
other advantages to participation in clinical trials. In addition, there were eleven 
respondents in the nonparticipant category that specified “Knowledge obtained is 
beneficial”, and five specified “If a clinical trial helps find a cure for a particular disease” 
as other advantages to participation in clinical trials.
Disadvantages for the Individual of Participation in Clinical Research Trials 
Objective (Ic, Part II) was to describe African Americans who were potential 
participants in clinical research trials on perceived disadvantages for the individual of 
participation in clinical research trials. To measure the perceived disadvantages for the 
individual of participation in clinical research trials, a six item scale was used. The 
response scale utilized was a five-point Likert-type scale with values ranging from 1 = 
“Strongly Disagree” to 5 = “Strongly Agree.” The middle point (3) on the scale did 
allow the respondents the option of an “Unsure” answer. To aid in the interpretation of 
this data, the researcher established an interpretive scale based on the responses available 
to the study participants. This scale had descriptions and corresponding values as 
follows: 1.00 to 1.50 = “Strongly Disagree;” 1.51 to 2.50 = “Disagree;” 2.51 to 3.49 = 
“Unsure;” 3.50 to 4.49 = “Agree;” and 4.50 to 5.00 = “Strongly Agree.”
When the data from the responses to the six items on the scale were examined, 
the statement with which the participants most strongly agreed was, “Experiencing side 
effects of the treatment” (mean = 3.26, SD = 1.10). This statement was classified using 
the interpretive scale as “Unsure.” The statement with which participants least agreed 
was, “Being treated like a “guinea pig” (mean = 2.71, SD = 1.25). The mean response
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to this statement was classified in the “Unsure” category. Overall, all six items were 
classified in the “Unsure” category (see Table 9).
Table 9
Perceived Disadvantages of Participation in Clinical Research Trials of Potential African 
American Participants
Item n Mean* SD Classificationb
Experiencing side effects of 
the treatment.
384c 3.26 1.10 Unsure
Disrupting one’s normal 
daily routine.
379d 3.15 1.19 Unsure
Having to miss work. 1*> 00 2.99 1.27 Unsure
Having to arrange childcare. 373r 2.89 1.26 Unsure
Losing one’s privacy.
oofO 2.72 1.16 Unsure
Being treated like a “guinea
_ *  «pig.
384c 2.71 1.25 Unsure
“Response scale: I = strongly disagree; 2 -  disagree; 3 = unsure, 4 = agree; 5 = strongly 
agree.
bMean responses were classified using the following descriptors for specified value 
ranges: 1.00-1.50 = strongly disagree; 1.51-2.50 = disagree; 2.51-3.49 = unsure; 3.50-
4.49 = agree; 4.50-5.00 = strongly agree.
Tw o respondents did not answer this item. 
dSeven respondents did not answer this item.
“Four respondents did not answer this item.
Thirteen respondents did not answer this item.
To further summarize the information regarding perceived disadvantages for the
individual of participation in clinical research trials, the researcher used factor analysis to
determine if underlying constructs could be identified in the scale. The analysis
procedure used was principal components analysis with a varimax rotation method.
The first step in conducting the factor analysis was to determine the optimum
number of factors to be extracted from the scale. Using a combination of the latent root
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criterion, the a ' priori criterion, and the scree test criterion, the number of factors to be 
extracted was determined to be one. The results of the factor analysis including the fac­
tor, it’s label based on the content of the items included in the factor, the percentage of 
variance explained by the factor, and factor loadings for each of the items in the factor is 
presented in Table 10. Since only one factor was extracted, the varimax rotation method 
was not applicable. The sub-scale was labeled by the researcher as “Drawbacks.” The 
only factor identified in the scale related to circumstances that would hinder participation 
in clinical research trials. Items in this factor included, “Having to miss work”, “Disrupt­
ing one’s normal daily routine”, “Having to arrange childcare,” “Experiencing side 
effects of the treatment”, “Losing one’s privacy”, and “Being treated like a “guinea pig.” 
The factor loadings ranged from a high of .80 to a low of .69 and explained 58.2 percent 
o f the overall variance in the scale (see Table 10).
Table 10
Factor Analysis of Perceived Disadvantages of Participation in Clinical Research Trials 
of Potential African American Participants
Factor- Drawbacks 
(explained 58.2% of variance)
Factor
Having to miss work. .80
Disrupting one’s normal daily routine. .80
Having to arrange childcare. .77
Experiencing side effects of the 
treatment.
.76
Losing one’s privacy. .75
Being treated like a “guinea pig.” .69
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Since all the items loaded on one factor, the researcher computed a disadvantage 
scale score. This scale score was identified as the mean of the items included in the 
factor. The disadvantage scale was labeled by the researcher as “Drawbacks.” This scale 
had individual subject mean scores that ranged from a low of 2.69 to a high of 3.25 with 
an overall mean of 2.95 (SD = .92). Using the interpretive scale, this scale received an 
overall rating classified as “Unsure.”
In addition to the six specified disadvantages, respondents were provided the 
opportunity to indicate an “Other” perceived disadvantage. If they did so, they were also 
asked to specify what this “Other” disadvantage was. The respondents overall list of 
“Other9' disadvantages to participation in clinical research trials were combined into the 
categories: participants (see Appendix D, question 31) and nonparticipants (see Appen­
dix E, question 31). There were ten respondents in the participant category that speci­
fied “Dates and times can't be changed or rescheduled, inconvenient,” five specified 
“Forcing someone to overeat to maintain a specific weight; many studies are too long” 
and, four individuals specified “Trip to clinic” as other disadvantages for the individual of 
participation in clinical research trials. In addition, eleven nonparticipants specified 
“Risk to your health,” seven specified “Getting to clinic,” four specified ‘Time consum­
ing; inconvenient,” three specified “Overcoming past atrocities where African Americans 
were deliberately infected (i.e. syphilis virus),” and, three specified “Not knowing if you 
are receiving treatment or sugar pill” as other disadvantages for the individual of partici­
pation in clinical research trials.
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Characteristics of Current and Past Participation in Clinical Research Trials 
Objective one (d) was to describe African Americans who were potential partici­
pants in clinical research trials on characteristics of current and past participation in 
clinical research trials. Respondents were asked a series of six questions that were 
designed to accomplish this part of the descriptive objective. First, they were asked if 
they had ever been asked to participate in a clinical trial. More than half (n = 213, 
55.3%) indicated that they had been asked to participate in a clinical trial (see Table 11). 
In addition, study participants were asked if they had previously participated in a clinical 
trial. Slightly more than a third of the participants (n = 145,37.7%) indicated a response 
of “Yes” to this question. However, when asked if they were currently participating in a 
clinical trial, a total of 64 (16.7%) indicated that they were currently enrolled in a clinical 
research trial (see Table 11).
Those individuals who responded “No” to all three of the initial items asked 
above were asked if they would participate in clinical research trials in the future if they 
were invited to do so. Of the eligible respondents to this item, 111 (90.2%) indicated 
that they would participate in the future if they were asked (see Table 11).
Participants were also asked to report whether or not they had ever decided to 
decline participation in a clinical trial after they had been classified as eligible to be a 
research participant The majority of the participants (n = 288,78.3%) indicated a “No” 
response to this question. Respondents were provided a list of possible reasons for 
choosing not to participate in the research activity and were asked to identify the primary 
reason for their negative decision. The reason that was identified most often was,
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Table 11
Clinical Research Trial Current and Past Participation Status o f  African Americans
Item Yes No Total
n % n % n %
Have you ever 
been asked to 
participate in a 
clinical trial?
213 55.3 172 44.7 385* 100
Have you previous­
ly participated in a 
clinical trial?
145 37.7 240 62.3 385“ 100
Are you currently 
enrolled in a clini­
cal trial?
64 16.7 320 83.3 384b 100
If you were asked 
to participate in a 
clinical trial in the 
future, would you 
participate?
111 90.2 12 9.8 123° 100
Have you ever 
decided not to 
participate in a 
clinical trial after 
being eligible?
80 21.7 288 78.3 368" 100
“One respondent did not answer this item.
'Two respondents did not answer this item.
This item was not applicable for 263 respondents.
''Eighteen respondents did not answer this item.
“Changed jobs, schedule would not permit” (n = 20,26.3%). Each of two other reasons 
were identified by 12 (15.8%) of the study participants. These reasons were, “Changed 
mind, due to fear” and “Live too far from the research center” (see Table 12). Seventeen 
of the respondents indicated that some “Other” reason was their primary reason for 
choosing not to participate. These individuals were also asked to specify what that
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“Other” reason was. Some of the “Other” primary reasons for choosing not to partici­
pate was, “Busy schedule,” and “Hours of participation were during work hours” (see 
Appendices D and E for a complete list).
Table 12
Primary Reason Cited for Not Participating bv African Americans Who Were Eligible 
But Chose Not to Participate in Clinical Research Trials
Item n %
Changed jobs, schedule 
would not permit.
20 26.3
Changed mind, due to fear. 12 15.8
Live too far from research 
center.
12 15.8
Too much effort involved. 8 10.5
Too many lab tests 
required.
6 7.9
Work too far from 
research center.
1 1.3
Other* (please specify) 17 22.4
Total 76b 100
*A complete listing of other reasons reported by respondents is presented in Appendices 
D andE.
'Tour respondents did not answer this item.
Exposure to Selected Experiences Which are Preliminary to Participation in Clinical
Research Trials
Objective one (e) was to describe African Americans who were potential partici­
pants in clinical research trials based on exposure to selected experiences which are pre­
liminary to participation in clinical research trials. Respondents were asked a series of 
four questions that were designed to accomplish this part of the descriptive objective.
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First, they were asked if  they received any verbal or written materials that described what 
the clinical trial was about and what they would need to do. More than half (n = 242, 
66.5%) indicated that they did receive verbal or written materials that described what the 
clinical trial was about and what they would need to do (see Table 13). Second, study 
participants were asked if they talked to family or friends before making their decision to 
participate or not participate in a clinical research trial. More than half (n = 217,59.6%) 
indicated that they did not talk to family or friends before making their decision to parti­
cipate or not participate in a clinical research trial (see Table 13). Third, study partici­
pants were asked if they talked to their doctor before making their decision to participate 
or not participate in a clinical research trial. Two hundred ninety eight (81.6%) of study 
participants did not talk with their doctor before making their decision to participate or 
not participate in a clinical research trial (see Table 13). Finally, study participants were 
asked if they had a family history of the disease being researched that prompted their 
decision to participate or not participate in a clinical research trial. Slightly more than 
half (n = 184,51.1%) indicated that they did not have a family history of the disease 
being researched that prompted their decision to participate or not participate in a 
clinical research trial as shown in Table 13.
In addition to the four specified exposures to selected experiences which are pre­
liminary to participation in clinical research trials, respondents were provided the oppor­
tunity to indicate an “Other” exposure to selected experiences which are preliminary to 
participation in clinical research trials. The respondents overall list of other selected 
experiences were combined into the categories: participants (see Appendix D, question 
42) and nonparticipants (see Appendix E, question 42). The responses varied for exam-
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Table 13
Exposure to Selected Experiences bv Potential African Americans Which are Preliminary 
to Participation in Clinical Research Trials
Item Yes No Unsure Total
n % n % n % n %
Did you receive any verbal 
or written materials that 
described what the clinical 
trial was about?
242 66.5 98 26.9 24 6.6 364* 100
Did you talk to family or 
friends before making your 
decision?
133 36.5 217 59.6 14 3.8 364“ 100
Did you talk to your 
doctor before making your 
decision?
55 15.1 298 81.6 12 3.3 365b 100
Did you have a family 
history o f the disease being 
researched?
149 41.4 184 51.1 27 7.5 360c 100
“Twenty two respondents did not answer this item. 
‘Twenty one respondents did not answer this item. 
Twenty six respondents did not answer this item.
pie, the participant category had 17 respondents that specified “Having family history of
disease,” while 12 in the nonparticipant category specified “Never asked to participate”
and another 12 nonparticipants specified “Did not fit profile,” as other exposures to
selected experiences which are preliminary to participation in clinical research trials.
Perceptions Regarding the Need for Selected Changes in Preparation for Participation in
Clinical Research Trials
Objective one (f) was to describe African Americans who were potential partici­
pants in clinical research trials on their perception regarding the need for selected 
changes in preparation for participation in clinical research trials. To measure
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perceptions regarding the need for selected changes in preparation for participation by 
African Americans in clinical research trials, a six item scale was used. The response 
scale utilized was a five-point Likert-type scale with values ranging from 1 = “Strongly 
Disagree” to 5 = “Strongly Agree.” The middle point (3) on the scale did allow the 
respondents the option of an “Unsure” answer. To aid in the interpretation of this data, 
the researcher established an interpretive scale based on the responses available to the 
study participants. This scale had descriptions and corresponding values as follows: 1.00 
to 1.50 = “Strongly Disagree;” 1.51 to 2.50 = “Disagree;” 2.51 to 3.49 = “Unsure;” 3.50 
to 4.49 = “Agree;” and 4.50 to 5.00 = “Strongly Agree.”
When the data from the responses to the six items on the scale were examined, 
the statement with which the participants most strongly agreed was, “Hearing about the 
good things that have been discovered from clinical trials” (mean = 4.37, SD = .76).
This statement was classified using the interpretive scale as “Agree.” The statement with 
which participants least agreed was, “Informational meeting about the clinical trial, 
presented by the nurse” (mean = 3.91, SD = .97). The mean response to this statement 
was classified in the “Agree” category (see Table 14).
To further summarize the perceptions regarding the need for selected changes in 
preparation for participation in clinical research trials, the researcher used factor analysis 
to determine if underlying constructs could be identified in the scale. The analysis proce­
dure used was principal components analysis with a varimax rotation method.
The first step in conducting the factor analysis was to determine the optimum 
number of factors to be extracted from the scale. Using a combination of the latent root
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Table 14
Perceptions Regarding the Need for Selected Changes in Preparation for Participation of 
Potential African Americans in Clinical Research Trials
Item n Mean1 SD Classification15
Hearing*about the good things 
that have been discovered from 
clinical trials.
381c 4.37 .76 Agree
Informational meeting about the 
clinical trial presented by the 
physician.
382“ 4.27 .83 Agree
Talking to other African 
Americans who have taken part 
in clinical trials.
oOO 4.18 .93 Agree
TV shows or videotapes with 
African Americans in clinical 
trials.
380e 4.00 1.01 Agree
Informational meeting about the 
clinical trial presented by 
African Americans.
381c 3.98 .99 Agree
Informational meeting about the 
clinical trial presented by the 
nurse.
o00 3.91 .97 Agree
“Response scale: 1 = strongly disagree; 2 -  disagree; 3 = unsure, 4 = agree; 5 = strongly 
agree.
'’Mean responses were classified using the following descriptors for specified value 
ranges: 1.00-1.50 = strongly disagree; 1.51-2.50 = disagree; 2.51-3.49 = unsure; 3.50-
4.49 = agree; 4.50-5.00 = strongly agree.
Tive respondents did not answer this item.
‘‘Four respondents did not answer this item. 
cSix respondents did not answer this item.
criterion, the a ' priori criterion, and the scree test criterion, the number of factors to be 
extracted was determined to be one. The results of the factor analysis including the fac-
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tor, it’s label based on the content of the items included in the factor, the percentage of 
variance explained by the factor, and factor loadings for each of the items in the factor 
is presented in Table 15. Since only one factor was extracted, the varimax rotation 
method was not applicable. The sub-scale was labeled by the researcher as “Ideas/ 
Suggestions.” The only factor identified in the scale related to ideas/suggestions for 
ways to help people learn more about clinical research trials. Items in this factor includ­
ed, “Informational meeting about the clinical trial presented by African Americans,” “TV 
shows or videotapes with African Americans in clinical trials”, “Talking to other African 
Americans who have taken part in clinical trials”, “Hearing about the good things that 
have been discovered from clinical trials”, “Informational meeting about the clinical trial 
presented by the physician”, and “Informational meeting about the clinical trial presented 
by the nurse.” The factor loadings ranged from a high of .79 to a low of .64 and 
explained 55.1 percent of the overall variance in the scale (see Table 15).
Table 15
Factor Analysis of Perceptions Regarding the Need for Selected Changes in Preparation 
for Participation of Potential African Americans in Clinical Research Trials
Factor- Ideas/Suggestions 
(explained 55.1% of variance)
Factor
Informational meeting about the clinical 
trial, presented by African Americans.
.79
TV shows or videotapes with African 
Americans in clinical trials.
.78
Talking to other African Americans who 
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Hearing about the good things that have 
been discovered from clinical trials.
.73
Informational meeting about the clinical 
trial, presented by the physician.
.72
Informational meeting about the clinical 
trial, presented by the nurse.
.64
Since all the items loaded on one factor, the researcher computed an ideas/ 
suggestion scale score. This scale score was identified as the mean of the items included 
in the factor. The “Ideas/Suggestions” scale had individual subject mean scores that 
ranged from a low of 3.92 to a high of 4.37 with an overall mean of 4.12 (SD = .68). 
Using the interpretive scale, this scale received an overall rating classified as “Agree.”
In addition to the six specified perceptions regarding the need for selected 
changes in preparation for participation in clinical research trials, respondents were 
provided the opportunity to indicate an “Other” perceptions regarding the need for 
selected changes in preparation for participation in clinical research trials. The respon­
dents overall list of other perceptions regarding the need for selected changes in prepara­
tion for participation in clinical research trials were combined into the categories: 
participants (see Appendix D, question 49) and nonparticipants (see Appendix E, 
question 49). The responses varied for example, nine respondents in the participant 
group specified “More advertising in African American periodicals, TV commercials 
with African Americans, post newsletters in African American communities.” There were 
six respondents in the nonparticipant category that specified “Research about the test not 
just from African Americans but whomever has participated.”
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Demographic Characteristics
Objective one (g) was to describe African Americans who were potential partici­
pants in clinical research trials on selected personal demographic characteristics. 
Respondents were asked to provide personal background information in the following 
areas: (1) gender, (2) age, (3) marital status, (4) education level, (5) employment status, 
(6) household income, (7) distance from research center, and (8) overall health status.
• Gender. The largest group (n = 308,79.8%) of respondents were female 
and 20.2% (n = 78) were male.
• Age. Respondents were given several age groups and asked to select the 
category that represented their age. The largest age group (n = 133, 
34.5%) of respondents selected the 46-55 year group. The second largest 
age group (n = 107,27.8%) of respondents was the 36-45 years group. 
The remaining age groups are shown in Table 16.
Table 16
Age Group of Potential African American Participants in a Clinical Research Trial
Item n %
< 18 years 1 .3
18-25 yrs. 23 6.0
26-35 yrs. 55 14.3
36-45 yrs. 107 27.8
46-55 yrs. 133 34.5
56-65 yrs. 51 13.2
66 yrs. and over 15 3.9
(Table continues)
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Total 385* 100.0
•One respondent did not answer this item.
• Marital Status. Respondents were asked to choose whether they were 
married, divorced/separated, never married or widowed. The largest 
group (n = 192,49.9%) of respondents indicated they were married. The 
second largest group (n = 98,25.5%) of respondents were 
divorced/separated. Responses for all categories of marital status are 
shown in Table 17.
Table 17




Never married 70 18.2
Widowed 25 6.5
Total 385* 100.0
•One respondent did not answer this item.
• Education. Respondents were given a list of education levels and asked 
to select the highest education level they had completed. The largest 
group (n = 151,39.3%) of respondents indicated that they had completed 
1-3 years of college/business or technical school. The second largest 
group (n = 82,21.4%) of respondents had a college degree. The third 
largest group (n = 67,17.5%) o f respondents had post graduate degrees. 
The respondents* education levels are shown in Table 18.
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Table 18
Education Level of Potential African American Participants in a Clinical Research Trial
Item n %
Grades 0-8 4 1.0
Some High School (HS) 27 7.0




College degree 82 21.4
Post graduate degree 67 17.5
Total 384i 100.0
“Two respondents did not answer this item.
• Employment status. Respondents were asked to indicate their present 
employment status. The largest group (n = 271,70.4%) of respondents 
indicated they were employed full time. The employment status for all 
respondents is shown in Table 19.
Table 19






Part time 31 8.0
Medical disability 18 4.7
(Table continues)
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"One respondent did not answer this item.
• Household income. Respondents were asked to indicate their
approximate household income. The largest group (n = 76,20.5%) of 
respondents indicated a house- hold income in the $20,000 - $29,999 
range. The second largest group (n = 67,18.1%) of respondents 
indicated a household income of $70,000 and up. The third largest group 
(n = 62,16.7%) of respondents indicated a household income of $10,000 
- $19,999 per year. Household income of respondents is presented in 
Table 20.
Table 20
Household Income of Potential African American Participants in a Clinical Research 
Trial
Item n %
<$10,000 per year 52 14.0
$10,000-$19,999 62 16.7
$20,000 - $29,999 76 20.5
$30,000 - $39,999 42 11.3
$40,000 - $49,999 30 8.1
$50,000 - $59,999 42 11.3
$70,000 and above 67 18.1
Total 371" 100.0
"Fifteen respondents did not answer this item.
• Distance from Respondents Domicile to Research Center. Respondents 
were asked to indicate the approximate distance from their domicile to
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the research center from a list of specified distances. The largest group (n 
= 115,30.4%) of respondents indicated that they lived within 15 miles of 
the research center. One hundred two (27.0%) of respondents indicated 
that they lived within 7 miles of the research center (see Table 21).
Table 21
Distance to the Research Center from Domicile Reported bv Potential African American 
Participants in a Clinical Research Trial
Item n %
Within 3 miles 57 15.0
Within 7 miles 102 27.0
Within 15 miles 115 30.4
Within 20 miles 52 13.8
More than 20 miles 52 13.8
Total
00 100.0
‘Eight respondents did not answer this item.
Distance from Respondents Worksite to the Research Center. 
Respondents were also asked to report the approximate distance from 
their worksite to the research center. The largest group (n = 99,30.2%) 
of respondents indicated that their worksite was within 7 miles o f the 
research center. The second largest group (n = 78,23.8%) of 
respondents indicated that they worked within 15 miles of the research 
center. The third largest group (n = 61,18.6%) of respondents indicated 
that they worked with 3 miles of the research center (see Table 22).
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Table 22
Distance to the Research Center from Worksite Reported bv Potential African American 
Participants in a Clinical Research Trial
Item n %
At Research Center 13 4.0
Within 3 miles 61 18.6
Within 7 miles 99 30.2
Within 15 miles 78 23.8
Within 20 miles 35 10.6
More than 20 miles 42 12.8
Total 328“ 100.0
“Fifty eight respondents did not answer this item.
Overall Health Status. Respondents were asked to indicate the item that 
best described their current health status. The largest group (n = 152, 
39.5%) of respondents indicated that they were in “Good” health. The 
second largest group (n = 126,32.7%) of respondents indicated they 
were in “Very Good” health. The health status of respondents is shown 
in Table 23.
Table 23












"One respondent did not answer this item.
Objective Two
Objective two (a) of the study was to describe and compare African Americans 
who have participated in clinical research trials and those who have not participated in 
clinical research trials on selected perceptual and demographic measures. The first of 
these measures was knowledge of clinical research processes. The first step in this pro­
cess was to describe the research respondents on their knowledge of clinical research 
trials. As identified previously, knowledge was measured using seven items to which 
respondents were asked to respond using a five point Likert-type scale. The item with 
which the participant group most strongly agreed was “Volunteers can refuse to partici­
pate in a clinical trial” (Mean = 4.73) (see Table 24). The item with which participants 
were found to exhibit the lowest level of agreement was “Volunteers are made aware of 
any possible complications or side effects of taking part in a clinical trial” (Mean = 4.17). 
The nonparticipants in the study reported the highest level of agreement with the same 
item as the participant group. This item was “Volunteers can refuse to participate in a 
clinical trial” (Mean = 4.52). However, the item with which nonparticipants expressed 
the lowest level of agreement was “Volunteers usually receive a cash stipend for 
participation in a clinical trial” with a mean rating of 3.81 (see Table 24).
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Table 24
Level of Knowledge of Clinical Research Trials Among African Americans bv Participa­
tion Status
Item Participants Nonparticipants
Mean* SD Mean* SD
Volunteers can refuse to 
participate in a clinical 
trial.
4.73 .48 4.52 .76
Clinical trials are needed to 
study the effects of 
treatments.
4.50 .64 4.44 .70
Volunteers can change 
their mind at any time and 
withdraw from a clinical 
trial.
4.46 .83 4.02 1.03
Volunteers receive infor­
mation needed to decide 
whether they want to take 
part in a clinical trial.
4.45 .73 3.86 1.14
Volunteers usually receive 
a cash stipend for partici­
pation in a clinical trial.
4.28 .78 3.81 .90
Volunteers are told about 
the possible risks and 
benefits of taking part in a 
clinical trial.
4.20 .91 4.00 1.01
Volunteers are made 
aware of any possible 
complications or side 
effects of taking part in a 
clinical trial.
4.17 .95 3.91 1.03
“Response scale: 1 = strongly disagree; 2 = cisagree; 3 = unsure, 4 = agree; 5 = strongly
agree. Mean responses were classified using the following descriptors for specified value 
ranges: 1.00-1.50 = strongly disagree; 1.51-2.50 = disagree; 2.51-3.49 = unsure; 3.50- 
4.49 = agree; 4.50-5.00 = strongly agree.
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To accomplish the second aspect o f this objective, the researcher needed to com­
pare the participants and nonparticipants on their level of knowledge of clinical research 
trials. However, to conduct individual statistical comparisons on each of the items used 
in the knowledge scale would have created an unacceptably inflated alpha level due to 
the inflation of experiment-wise error which occurs when related items are used in 
multiple statistical comparisons. Therefore, to accomplish this task, the researcher 
utilized the underlying constructs and the corresponding sub-scale scores derived from 
the factor analysis in objective one of the study.
When these two sub-scale scores were compared by participation status of the 
study respondents using the independent samples t-test procedure, the results showed 
that the two groups were significantly different on both of the sub-scale scores. On the 
first knowledge factor which was labeled by the researcher as “Information Provided,” 
the participant group had a mean score of 4.28 (SD = .63) and the nonparticipant group 
had a mean score of 3.90 (SD = .81) (t 3g4 = 4.943, p < .001). This indicated that the 
participant group reported significantly higher levels of agreement with items in the 
“Information Provided” knowledge factor than did the nonparticipants.
For the second knowledge factor, labeled as “Awareness” by the researcher, simi­
lar results were found (t 3g4 = 4.093, p < .001). With the mean values for the groups 
identified as 4.57 (SD = .48) for the participant group and 4.32 (SD = .63) for the non­
participant group, these results also indicated that the participants had a significantly 
higher level of agreement with the items in the “Awareness” knowledge factor than did 
the nonparticipants.
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Objective two (b) of the study was to describe and compare African Americans 
who have participated in clinical research trials and those who have not participated in 
clinical research trials on their perceptions of clinical research purposes and procedures. 
The first step in objective two (b) was to describe the research respondents on their 
perceptions of clinical research purposes and procedures. As identified previously, 
perceptions were measured using eight items to which respondents were asked to 
respond using a  five point Likert-type scale. The item with which the participant group 
most strongly agreed was “Participation in a clinical trial can help future generations” 
(Mean = 4.59) (see Table 25). The item with which participants were found to exhibit 
the lowest level of agreement with was “Participation in a clinical trial can prevent a 
disease” (Mean = 3.35). The item with which the nonparticipants most strongly agreed 
was “Clinical trials are a necessary way to learn about treatments” (Mean = 4.39) (see 
Table 25). The item with which the nonparticipants expressed the lowest level of 
agreement was “Participation in a clinical trial can delay a disease” (Mean = 3.07). 
Table 25
Perceptions of Clinical Research Trials Among African Americans bv Participation 
Status
Item Participants Nonparticipants
Mean1 SD Mean1 SD
Participation in a clinical 
trial can help future 
generations.
4.59 .55 4.37 .70
Participation in a clinical 
trial can help me and my 
family.
439 .70 4.09 .85
(Table continues)
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Clinical trials are a neces­
sary way to learn about 
treatments.
4.39 .76 4.39 .77
The information in the 
consent form is important 
to help volunteers decide 
about participation in a 
clinical trial.
4.37 .75 4.18 .84
It is important for people 
to take part in clinical 
trials.
4.32 .79 4.18 .86
Blood work is necessary in 
a clinical trial.
4.30 .84 3.96 .97
Participation in a clinical 
trial can delay a disease.
3.37 1.11 3.07 1.16
Participation in a clinical 
trial can prevent a disease.
3.35 1.13 3.16 1.20
•Response scale: 1 = strongly disagree; 2 = disagree; 3 = unsure, 4 = agree; 5 = strongly 
agree. Mean responses were classified using the following descriptors for specified value 
ranges: 1.00-1.50 = strongly disagree; 1.51-2.50 = disagree; 2.51-3.49 = unsure; 3.50-
4.49 = agree; 4.50-5.00 = strongly agree.
To accomplish the second aspect of objective two (b), the researcher needed to 
compare the participants and nonparticipants on their perceptions of clinical research 
purposes and procedures. However, to conduct individual statistical comparisons on 
each of the items used in the perception scale would have created an unacceptably 
inflated alpha level due to the inflation of experiment-wise error. Therefore, to accom- 
lish this task, the researcher utilized the underlying constructs and the corresponding 
sub-scale scores derived from the factor analysis in objective one.
When these two sub-scale scores were compared by participation status of the 
study respondents using the independent samples t-test procedure, the results showed 
that the two groups were significantly different on both o f the sub-scale scores. On the
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first perception factor which was labeled by the researcher as “Participation Benefits,” 
mean scores included for the participant group 4.39 (SD = .54) and for the nonpartici­
pant group 4.19 (SD = .62)(t 3g4 = 3.249, j> = .001). This indicated that the participant 
group reported significantly higher levels of agreement with items in the “Participation 
Benefits” perception factor than did the nonparticipants.
For the second perception factor, labeled as “Prevention” by the researcher, simi­
lar results were found (t 384 “ 2 .241, £ = .026). With the mean values for the groups 
identified for the participant group as 3.37 (SD -  1.07) and for the nonparticipant group 
3.12 (SD = 1.09) these results also indicated that the participants had a significantly 
higher level of agreement with the items in the “Prevention” perception factor than did 
the nonparticipants.
Objective two (c) Part I was to describe and compare African Americans who 
have participated in clinical research trials and those who have not participated in clinical 
research trials on perceived advantages for the individual of participation in clinical 
research trials. The first step in this process was to describe the research respondents on 
their perceived advantages for the individual of participation in clinical research trials.
As identified previously, the perceived advantages were measured using eight items to 
which respondents were asked to respond using a five point Likert-type scale. The item 
with which the participant group most strongly agreed was “Doing something that will 
help others” (Mean = 4.51) (see Table 26). The item with which participants were found 
to exhibit the lowest level of agreement with was “Getting free medications” (Mean = 
3.61). '‘The nonparticipants in the study reported the highest level of agreement with the 
same item as the participant group. This hem was “Doing something that will help
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others” (Mean = 4.36). However, the item with which nonparticipants expressed the 
lowest level of agreement was “Helping to delay a disease” with a mean rating of 3.46 
(see Table 26).
Table 26
Perceived Arivantapes of Clinical Research Trials Among African Americans hv 
Participation Status
Item Participants Nonparticipants
Mean* SD Mean* SD
Doing something that will 
help others.
4.51 .58 4.36 .62
Getting better care and 
follow-up (for example, 
with laboratory tests).
4.40 .79 4.06 .83
Doing something positive 
for self.
4.38 .74 4.09 .86
Getting a cash stipend. 3.99 .97 3.54 .99
Receiving the newest 
treatment.
3.88 .90 3.96 .83
Helping to prevent a 
disease.
3.78 1.02 3.70 .98
Helping to delay a disease. 3.70 1.05 3.46 1.01
Getting free medications. 3.61 1.14 3.48 .97
'Response scale: 1 = strongly disagree; 2 = disagree; 3 = unsure, 4 = agree; 5 = strongly
agree. Mean responses were classified using the following descriptors for specified value 
ranges: 1.00-1.50 = strongly disagree; 1.51-2.50 = disagree; 2.51-3.49 = unsure; 3.50-
4.49 = agree; 4.50-5.00 = strongly agree.
To accomplish the second aspect of Part I of this objective, the researcher needed 
to compare the participants and nonparticipants on their perceived advantages for the in­
dividual of participation in clinical research trials. However, to conduct individual statis-
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tical comparisons oa each of the items used in the advantage scale would have created an 
unacceptably inflated alpha level due to the inflation of experiment-wise error. Therefore, 
to accomplish this task, the researcher utilized the underlying construct and the corre­
sponding sub-scale score derived from the factor analysis conducted in objective one.
When this sub-scale score was compared by participation status o f the study 
respondents using the independent samples t-test procedure, the results showed that the 
two groups were significantly different. There was one advantage factor labeled by the 
researcher as “Primary Benefits” with a mean score of 4.03 (SD = .60) for the participant 
group and 3.83 (SD = .61) for the nonparticipant group (t 384 = 3.179, p = .002). This 
indicates that the participant group reported significantly higher levels of agreement with 
items in the “Primary Benefits” advantage factor than did the nonparticipants.
Objective two (c) Part II was to describe and compare African Americans who 
have participated in clinical research trials and those who have not participated in clinical 
research trials on perceived disadvantages for the individual of participation in clinical 
research trials. The first step in this process was to describe the research respondents on 
their perceived disadvantages for the individual of participation in clinical research trials. 
The perceived disadvantages were measured using six items to which respondents were 
asked to respond using a five point Likert-type scale. The item with which the 
participant group most strongly agreed was “Experiencing side effects of the treatment” 
(Mean = 2.99) (see Table 27). The item with which participants were found to exhibit 
the lowest level of agreement with was “Being treated like a “guinea pig” (Mean = 2.31). 
The nonparticipants in the study reported the highest level of agreement with the same 
hem as the participant group. This item was “Experiencing side effects o f the treatment”
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(Mean = 3.46). However, the item with which nonparticipants expressed the lowest 
level o f agreement was “Losing one’s privacy” with a mean rating of 2.94 (see Table 
27).
Table 27
Perceived Disadvantages of Clinical Research Trials Among African Americans bv 
Participation Status
Item Participants Nonparticipants
Mean* SD Mean* SD
Experiencing side effects 
o f the treatment.
2.99 1.08 3.46 1.07
Disrupting one’s normal 
daily routine.
2.90 1.24 3.32 1.13
Having to miss work. 2.74 1.33 3.17 1.20
Having to arrange child­
care.
2.58 1.28 3.11 1.20
Losing one’s privacy. 2.39 1.11 2.94 1.14
Being treated like a 
“guinea pig.”
2.31 1.16 2.98 1.23
•Response scale: 1 = strongly disagree; 2 = cisagree; 3 = unsure, 4 = agree; 5 = strongly
agree. Mean responses were classified using the following descriptors for specified value 
ranges: 1.00-1.50 = strongly disagree; 1.51-2.50 = disagree; 2.51-3.49 = unsure; 3.50-
4.49 = agree; 4.50-5.00 = strongly agree.
To accomplish the second aspect of Part II of this objective, the researcher 
needed to compare the participants and nonparticipants on their perceived disadvantages 
for the individual of participation in clinical research trials. However, to conduct individ­
ual statistical comparisons on each of the items used in the disadvantage scale would 
have created an unacceptably inflated alpha level due to the inflation of experiment-wise 
error. Therefore, to accomplish this task, the researcher utilized the underlying construct
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and the corresponding sub-scale score derived from the factor analysis conducted in 
objective one.
When this sub-scale score was compared by participation status of the study 
respondents using the independent samples t-test procedure, the results showed that the 
two groups were significantly different on their perceptions regarding disadvantages for 
the individual of participation in clinical research trials. There was one disadvantage 
factor labeled by the researcher as “Drawbacks” with a mean score of 2.65 (SD = .87) 
for the participant group and 3.16 (SD = .90) for the nonparticipant group (t JM = -5.595, 
g < .001). This indicates that the nonparticipant group reported significantly higher 
levels of agreement with the items in the “Drawbacks” disadvantage factor than did the 
participants.
Objective two (d) was to describe and compare African Americans who have 
participated in clinical research trials and those who have not participated in clinical 
research trials on characteristics of their current and past participation in clinical research 
trials. A total of six aspects of clinical research participation status were examined as 
part of this objective. The first aspect was whether or not the respondents had ever been 
asked to participate in a clinical trial. For the participant group, the majority (n = 126, 
79.7%) of respondents indicated that they had been asked to participate in a clinical trial. 
In contrast, the majority of nonparticipants (n=  140,61.7%) indicated that they had not 
been asked to participate in a clinical trial (see Table 28).
The next part of this objective was to compare the participant and nonparticipant 
groups on whether or not they had ever been asked to participate in a clinical trial. This 
was accomplished using the Chi-square test of independence to determine if  the two
72
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Table 28
Crosstabulation of Clinical Research Trial Participation Status and Whether or Not
African Americans Indicated That They Had Ever Been Asked to Participate
Have vou ever been asked to participate 









Mote. X2(ij= 64.67, e  < .001
variables (whether or not they had participated and whether or not they had ever been 
asked to participate) were independent. The resulting calculated Chi-square value (x2,d 
= 64.67, p < .001) indicated that the variables were not independent. The nature of the 
association between the variables was such that a greater proportion of the participants 
indicated that they had been asked to participate while a greater proportion of the 
nonparticipants indicated they had not been asked to participate.
The second aspect of characteristics of current and past participation in clinical 
research trials was, whether or not the respondents had previously participated in a 
clinical trial. For the participant group, the majority (n = 114,72.2%) of respondents 
indicated that they had previously participated in a clinical trial. In contrast, the majority 
of nonparticipants (n = 196,86.3%) indicated that they had not previously participated in 
a clinical trial (see Table 29).
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Table 29
Crosstabulation of Clinical Research Trial Participation Status and Whether or Not
African Americans Indicated That They Had Previously Participated









Mote. x2,„= 135.77, B < . 001
The next part of this objective was to compare the participant and nonparticipant 
groups on whether or not they previously participated in a clinical trial. This was accom­
plished using the Chi-square test of independence to determine if the two variables 
(whether or not they participated and whether or not they had previously participated) 
were independent. The resulting calculated Chi-square value (X2(i>= 135.77, g < .001) 
indicates that the variables were not independent. The nature of the association between 
the variables was such that a greater proportion of the participants (72.2%) indicated 
that they previously participated while a greater proportion of the nonparticipants 
(86.3%) indicated they had not previously participated.
The third aspect of characteristics of current and past participation in clinical 
research trials was, whether or not the respondents were currently enrolled in a clinical 
trial. For the participant group, approximately one third (n = 53,33.5%) of respondents 
indicated they were currently enrolled in a clinical trial. In contrast, fewer of the
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nonparticipants (n= 11,4.9%) indicated that they were not currently enrolled in a 
clinical trial (see Table 30).
Table 30
Crosstabulation of Clinical Research Trial Participation Status and Whether or Not 
African Americans Indicated That They Were Currently Enrolled










Note. x2(l)= 55.06.p < .001
The next part of this objective was to compare the participant and nonparticipant 
groups on whether or not they were currently enrolled in a clinical trial. This was 
accomplished using the Chi-square test of independence to determine if the two variables 
(whether or not they had participated and whether or not they were currently enrolled) 
were independent. The resulting calculated Chi-square value (x2(I)= 55.06, g < .001) in­
dicated that the variables were not independent. The nature of the association between 
the variables was such that a greater proportion of the participants (33.5%) indicated 
that they were currently enrolled in a clinical trial while a greater proportion of the 
nonparticipants (95.1%) indicated they were not currently enrolled in a clinical trial.
The fourth aspect of characteristics of current and past participation in clinical 
research trials was, “If  you said “No” to ever been, previously, or currently enrolled in a 
clinical trial, and you were asked to participate in a  clinical trial in the future, would you
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participate?” This was accomplished using the Chi-square test of independence to 
determine if the two variables (whether or not they had participated and whether or not 
they would participate in a future clinical trial, if asked to do so) were independent. The 
resulting calculated Chi-square value (x2a>= -07, g = .79) was not significant, indicating 
that the two variables were independent.
The fifth aspect of characteristics of current and past participation in clinical 
research trials was whether or not the respondents had ever decided not to participate in 
a clinical trial after being eligible. For the participant group, less than one fourth (n = 24, 
15.6%) of respondents indicated that they had decided not to participate in a clinical trial 
after being eligible. In contrast, more than one fourth of nonparticipants (n = 56,26.2%) 
indicated that they had decided not to participate in a clinical trial after being eligible (see 
Table 31).
Table 31
Crosstabulation of Clinical Research Trial Participation Status and Whether or Not 
African Americans Decided Not to Participate After Being Eligible
Have vou ever decided not to participate 









sfote. x2(d= 5.90, g  = .0I5
The next part of this objective was to compare the participant and nonparticipant 
groups on whether or not they ever decided not to participate in a clinical trial after
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being eligible. This was accomplished using the Chi-square test of independence to 
determine if the two variables (whether or not they had participated and whether or not 
they ever decided not to participate in a clinical trial after being eligible) were independ­
ent. The resulting calculated Chi-square value (x2n)= 5.90, g  = .015) was significant, 
indicating that the variables were not independent. The nature of the association 
between the variables was such that a smaller proportion of the participants (15.6%) 
indicated they decided not to participate in a clinical trial after being eligible while a 
greater proportion of the nonparticipants (26.2%) indicated they had decided not to 
participate in a clinical trial after being eligible.
The sixth aspect of characteristics of current and past participation in clinical 
research trials was to select the primary reason respondents decided not to participate in 
a clinical trial after being eligible. For the participant group, the largest group (n = 5, 
25.0%) of respondents indicated “Other” as the primary reason they decided not to parti­
cipate in a clinical trial after being eligible. For the nonparticipants, the largest group (n 
= 17,30.4%) of respondents indicated “Changed jobs, schedule would not permit” (see 
Table 32) as their primary reason for deciding not to participate after being eligible. 
There was a total of 76 individuals responding to this aspect of clinical research partici­
pation status of which 17 indicated “Other” as their reason for not participating. Refer 
to Appendices D and E (question number 37) for a complete listing of participant and 
nonparticipant responses.
The next part of this objective was to compare the participant and nonparticipant 
groups on responses to the question, “If yes, what is the primary reason that you decided 
not to participate in a clinical trial.” Table 32 clearly indicates that the numbers required
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Table 32
Crosstabulation of Clinical Research Trial Participation Status and If Yes. Primary
Reason African Americans Decided Not to Participate
If yes, what is the primary reason that you decided Participation Status




Changed jobs, schedule would not permit 3 17
15.0% 30.4%
Live too far 3 9
15.0% 16.0%
Too much effort involved 3 5
15.0% 8.9%
Too many lab tests required 3 3
15.0% 5.4%
Changed mind, due to fear 2 10
10.0% 17.9%





"See Appendices D and E for a complete list of other reasons reported by respondents.
to conduct the Chi-square test of independence were not adequate and therefore, no 
reason to run the test to determine if  the two variables (whether or not they had 
participated and primary reason decided not to participate) were independent.
Objective two (e) was to describe and compare African Americans who have par­
ticipated in clinical research trials and those who have not participated in clinical research 
trials based on their exposure to selected experiences which are preliminary to participa-
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tion in clinical research trials. A total of four selected experiences preliminary to partici­
pation in clinical research trials were examined as part of this objective. The first 
experience was whether or not the respondents received any verbal or written materials 
that described what the clinical trial was about and what needed to be done. For the 
participant group, the majority (n = 137,88.4%) of respondents indicated that they 
received verbal or written materials that described what the clinical trial was about and 
what needed to be done. In contrast, only slightly more than half of the nonparticipants 
(n = 105,50.2%) indicated that they had received verbal or written materials that 
described what the clinical trial was about and what was needed to be done (see Table 
33).
Table 33
Onsstahulation of Clinical Research Trial Exposures and Whether or Not African 
Americans Indicated They Received Anv Verbal or Written Materials
Did you receive any verbal or written 
materials that described what the clinical 












Mote. x2(2)= 62.34, j>< .001
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The next part of this objective was to compare the participant and nonparticipant 
groups on whetheror not they received any verbal or written materials that described 
w. .c the clinical trial was about and what needed to be done. This was accomplished 
using the Chi-square test of independence to determine if the two variables (whether or 
not they participated and whether or not they received any verbal or written materials 
that described what the clinical trial was about and what needed to be done) were 
independent. The resulting Chi-square value (x2<2>= 62.34, g < .001) indicated that the 
variables were not independent. The nature of the association between the variables was 
such that a greater proportion of the participants indicated that they had received verbal 
or written materials that described what the clinical trial was about and what needed to 
be done while a greater proportion of the nonparticipants indicated that they had not 
received any verbal or written materials describing what the clinical trial about and what 
was needed to be done.
The second exposure to selected experiences which are preliminary to participa­
tion in clinical research trials was whether or not respondents talked to family or friends 
before making their decision to participate or not participate in a clinical trial. For the 
par- ticipant group, almost half (n = 75,48.1%) of respondents indicated that they talked 
to family or friends before making their decision to participate or not participate in a 
clinical trial. In contrast, only slightly more than one fourth of the nonparticipants (n -  
98,27.9%) indicated that they talked to family or friends before making their decision to 
participate or not participate in a clinical trial (see Table 34).
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Table 34
Crosstabulation of Clinical 'Research Trial Exposures and Whether or Not African 
Americans Indicated They Talked to Family or Friends Before Making Their Decision to 
Participate or Not Participate
Did you talk to family or friends before 












sfote. X2<2)= 15.93,p < .001
The next part of this objective was to compare the participant and nonparticipant 
groups on whether or not they talked to family or friends before making their decision to 
participate or not participate in a clinical trial. This was accomplished using the Chi- 
square test of independence to determine if the two variables (whether or not they had 
participated and whether or not they talked to family or friends before making their deci­
sion to participate or not participate) were independent. The resulting calculated Chi- 
square value (x2(2)= 15.93, p < .001) indicated that the variables were not independent 
The nature of the association between the variables was such that more of the partici­
pants indicated that they talked to family or friends before making their decision to parti­
cipate or not participate while the majority of the nonparticipants indicated they did not 
talk to family or friends before making their decision to participate or not participate in a 
clinical trial.
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The third exposure to selected experiences which are preliminary to participation 
in clinical research trials was whether or not the respondents talked to their doctor 
before making their decision to participate or not participate in a clinical trial. For the 
participant group, less than one fifth (n = 29, 18.6%) of respondents indicated that they 
talked to their doctor before making their decision to participate or not participate in a 
clinical trial. Slightly more than one tenth of the nonparticipants (n = 26, 12.4%) 
indicated that they talked to their doctor before making their decision to participate or 
not participate in a clinical trial (see Table 35).
Table 35
Crosstabulation of Clinical Research Trial Exposures and Whether or Not African 
Americans Indicated They Talked to Their Doctor Before Making Their Decision to 
Participate or Not Participate
Did you talk to your doctor before 












Note. x2f>)= 2.64, p  = .27
The next part of this objective was to compare the participant and nonparticipant 
groups on whether or not they talked to their doctor before making their decision to 
participate or not participate in a clinical trial. This was accomplished using the Chi-
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square test of independence to determine if the two variables (whether or not they had 
participated and whether or not they talked to their doctor before making the decision to 
partici- pate or not participate in a clinical trial) were independent. The resulting 
calculated Chi-square value (x2 o)= 2.64, g = .27) was not significant, indicating that the 
two variables were independent
The fourth exposure to selected experiences which are preliminary to 
participation in clinical research trials was whether or not the respondents had a family 
history of the disease being researched that prompted their decision to participate or not 
participate in a clinical trial. For the participant group, almost half (n = 71,47.0%) of 
the respondents indicated that they had a family history of the disease being researched 
that prompted their decision to participate or not participate in a clinical trial. In 
addition, a little more than a third of the nonparticipants (n = 78,37.3%) indicated that 
they had a family history of the disease being researched that prompted their decision to 
participate or not participate in a clinical trial (see Table 36).
The next part of this objective was to compare the participant and nonparticipant 
groups on whether or not they had a family history of the disease being researched that 
prompted their decision to participate or not participate. This was accomplished using 
the Chi-square test of independence to determine if the two variables (whether or not 
they had participated and whether or not they had a family history of the disease being 
researched that prompted their decision to participate or not participate in a clinical trial) 
were independent. The resulting calculated Chi-square value (x2(2)= 3.67, g = .16) was 
not significant, indicating that the two variables were independent.
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Table 36
Crosstabulation of Clinical Research Trial Exposures and Whether or Not African 
Americans Indicated They Had a Family History of the Disease That Prompted Their 
Decision to Participate or Not Participate
Did you have a family history of the 
disease being researched that prompted 












Note, x2 r ) = 3.67. p = . 16
Objective two (f) was to describe and compare African Americans who have par­
ticipated in clinical research trials and those who have not participated in clinical research 
trials on their perceptions regarding the need for selected changes in preparation for 
participation in clinical research trials. The first step in this process was to describe the 
research respondents on their perceptions regarding the need for selected changes in 
preparation for participation in clinical research trials. The perceptions regarding the 
need for selected changes in preparation for participation in clinical research trials were 
measured using six items to which respondents were asked to respond using a five point 
Likert-type scale. The item with which the participant group most strongly agreed was, 
“Hearing about the good things that have been discovered from clinical trials” (Mean = 
4.39) (see Table 37). The item which participants were found to exhibit the lowest level
84
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
of agreement with was, “Informational meeting about the clinical trial presented by 
African Americans” (Mean = 4.00). The nonparticipants in the study reported the 
highest level of agreement with the same item as the participant group. This item was 
“Hearing about the good things that have been discovered from clinical trials” (Mean = 
4.35) (see Table 37). However, the item with which nonparticipants expressed the 
lowest level of agreement was, “Informational meeting about the clinical trial presented 
by the nurse” (Mean = 3.82).
To accomplish the second aspect of this objective, the researcher needed to com­
pare the participants and nonparticipants on their perceptions regarding the need for 
selected changes in preparation for participation in clinical research trials. However, to 
conduct individual statistical comparisons on each of the items individually would have 
created an unacceptably inflated alpha level due to the inflation of experiment-wise error. 
Therefore, to accomplish this task, the researcher utilized the underlying construct and 
the corresponding sub-scale score derived from the factor analysis reported in objective 
one.
When the sub-scale score for perceptions regarding the need for selected changes 
in preparation for participation in clinical research trials was compared by participation 
status of respondents using the independent samples t-test procedure, the results showed 
that the two groups were not significantly different ( t381= 1.176, p = .24). There was 
one scale score regarding the perceived need for selected changes in preparation for 
participation in a clinical research trial factor labeled by the researcher as “Ideas/Sugges-
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Table 37
Perceptions Regarding the N eed for Selected Changes in Preparation for Clinical 
Research Trials Among African Americans hv Participation Status
Item Participants Nonparticipants
Mean* SD Mean* SD
Hearing about the good 
things that have been dis­
covered from clinical trials.
4.39 .79 4.35 .75
Informational meeting 
about the clinical trial 
presented by the physician.
4.39 .69 4.18 .90
Talking to other African 
Americans who have taken 
part in clinical trials.
4.17 .92 4.19 .94
Informational meeting 
about the clinical trial pre­
sented by the nurse.
4.05 .94 3.82 .99
TV shows or videotapes 
with African Americans in 
clinical trials.
4.01 1.00 4.00 1.01
Informational meeting 
about the clinical trial pre­
sented by African Ameri­
cans.
4.00 .97 3.96 1.00
•Response scale: 1 = strongly disagree; 2 = disagree; 3 = unsure, 4 = agree; 5 = strongly 
agree. Mean responses were classified using the following descriptors for specified value 
ranges: 1.00-1.50 = strongly disagree; 1.51-2.50 = disagree; 2.51-3.49 = unsure; 3.50-
4.49 = agree; 4.50-5.00 = strongly agree.
tions” with a mean score of 4.17 (SD = .63) for the participant group and 4.08 (SD -  
.70) for the nonparticipant group.
Objective two g (i) was to describe and compare African Americans who have 
participated in clinical research trials and those who have not participated in clinical 
research trials based on their gender. The majority (n=  121,76.6%) o f the respondents
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in the participant group were female and the majority (n = 187,82.0%) of the 
respondents in the nonparticipant group were female (see Table 38).
Table 38
Description of Participants and Nonparticipants in Clinical Research Trials bv Gender 
Among African Americans
Gender Participants Nonparticipants
n % n %
Female 121 76.6 187 82.0
Male 37 23.4 41 18.0
Total 158 100.0 228 100.0
Note. x2(i)= 1-71. p = .20
The second aspect of this objective was to compare the participant and nonparti­
cipant groups based on gender. This was accomplished using the Chi-square test of 
independence to determine if the two variables (whether or not they participated and 
whether they were male or female) were independent. The resulting calculated Chi- 
square value (X2(i)= 1-71, p = .20) was not significant, indicating that the two variables 
were independent.
Objective two g (ii) was to describe and compare African Americans who have 
participated in clinical research trials and those who have not participated in clinical 
research trials based on their age. The first aspect was to describe the participant and 
nonparticipant groups based on age. The largest number (n = 67,42.4%) of the 
respondents in the participant group were in the 46-55 year age group. The largest 
number (n = 70,30.8%) of the respondents in the nonparticipant group were in the 36- 
45 year age group. The second largest number (n = 37,23.4%) of respondents in the
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participant group were in the 36-45 year age group. The second largest number (n = 66, 
29.1%) of the respondents in the nonparticipant group were in the 46-55 year age group 
(see Table 39).
Table 39
Description of Participants and Nonparticipants in Clinical Research Trials by Age 
Among African Americans
Age Group Participants Nonparticipants
n % n %
< 18 years 1 0.6 0 0.0
18-25 years 12 7.6 11 4.8
26-35 years 11 7.0 44 19.4
36-45 years 37 23.4 70 30.8
46-55 years 67 42.4 66 29.1
56-65 years 25 15.8 26 11.5
66 years and over 5 3.2 10 4.4
Total 158 100.0 227* 100.0
Mote, x2 <6)= 21.02, g = .002
•One respondent did not answer this item.
The next part of this objective was to compare the participant and nonparticipant 
groups on whether or not they participated in clinical research trials based on age. This 
was accomplished using the Chi-square test of independence to determine if the two 
variables (whether they participated and age group) were independent. The resulting 
calculated Chi-square value (x2(6)= 21.02, j> = .002) indicated that the variables were not 
independent. The nature of the association between the variables was such that a greater 
proportion o f the participants were in the 46-55 year and the 56-65 year age categories
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while a greater proportion of the nonparticipants were in the 26-35 year and the 36-45 
year age range categories.
Objective two g (iii) was to describe and compare African Americans who have 
participated in clinical research trials and those who have not participated in clinical 
research trials based on their marital status. The first aspect was to describe the partici­
pant and nonparticipant groups based on marital status. Half (n = 79,50.0%) of the 
respondents in the participant group indicated they were married. Approximately half (n 
= 113,49.8%) of the respondents in the nonparticipant group indicated they were 
married. The next largest group (n = 36,22.8%) of the respondents in the participant 
group indicated they were divorced/separated. More than one fourth (n = 62,27.3%) of 
the respondents in the nonparticipant group indicated they were divorced/separated (see 
Table 40).
The second aspect of this objective was to compare the participant and nonparti­
cipant groups on whether or not they participated in clinical research trials based on 
marital status. This was accomplished using the Chi-square test of independence to 
determine if the two variables (whether they participated and whether they were married, 
divorced/ separated, never married, or widowed) were independent. The resulting 
calculated Chi-square value (x2(3)= 1.56, g = .67) was not significant, indicating that the 
two variables were independent.
Objective two g (iv) was to describe and compare African Americans who have 
participated in clinical research trials and those who have not participated in clinical 
research trials based on their education level. The first aspect was to describe the parti­
cipant and nonparticipant groups based on education level. Less than one third (n = 47,
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Table 40
Description of Participants and Nonparticipants in Clinical Research Trials bv Marital
Status A m rtnpr African Americans
Marital Status Participants Nonparticipants
n % n %
Married 79 50.0 113 49.8
Divorced/Separated 36 22.8 62 27.3
Never Married 31 19.6 39 17.2
Widowed 12 7.6 13 5.7
Total 158 100.0 227* 100.0
Note, x2 (3) = 1.56, g = .67
"One respondent did not answer to item.
29.9%) of the respondents in the participant group indicated 1-3 years college, business 
or technical school education level. Almost half (n = 104,45.8%) of the respondents in 
the nonparticipant group indicated 1-3 years college, business or technical school 
education level. Almost one fourth (n = 38,24.2%) of the respondents Li the participant 
group indicated they had college degrees. Less than one fifth (n = 44,19.4%) of the 
respondents in the nonparticipant group indicated they had college degrees (see Table 
41).
The next part of this objective was to compare the participant and nonparticipant 
groups on their level of education. This was accomplished using the Chi-square test of 
independence to determine if the two variables (whether they participated and education 
level) were independent. The resulting calculated Chi-square value (x2(j)= 13.47, g  = 
.02) indicated that the variables were not independent The nature of the association
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Table 41
Description of Participants and Nonparticipants in Clinical Research Trials bv Education
Level Among African Americans
Education Level Participants Nonparticipants
n % n %
Grades 0-8 3 2.0 1 0.4
Some High School 11 7.0 16 7.0
High School Diploma/GED 22 14.0 31 13.7
1 -3 years college, business 
or technical school
47 29.9 104 45.8
College degree 38 24.2 44 19.4
Post graduate degree 36 22.9 31 13.7
Total 157“ 100.0 227b 100.0
Note. x 2,s )=  13.47,p = .02
*One respondent did not answer to item. 
bOne respondent did not answer to item.
between the variables was such that a greater proportion of the participants reported 
college degree and post graduate degree as their highest level of education completed. 
Among the nonparticipants, a greater proportion indicated 1-3 years college, business or 
technical school as their highest level of education completed.
Objective two g (v) was to describe and compare African Americans who have 
participated in clinical research trials and those who have not participated in clinical 
research trials based on their employment status. The first aspect was to describe the 
participant and nonparticipant groups based on employment status. The majority (n = 
111, 70.3%) of the respondents in the participant group were employed full time. Like-
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wise, the majority (n = 160,70.5%) of the respondents in the nonparticipant group were 
employed full time (see Table 42).
Table 42
Description of Participants and Nonparticipants in Clinical Research Trials bv Employ 
ment Status Among African Americans
Employment Status Participants Nonparticipants
n % n %
Employed full time 111 70.3 160 70.5
Employed part-time 12 7.6 19 8.4
Retired 13 8.2 19 8.4
Unemployed 17 10.8 16 7.0
Medical disability 5 3.1 13 5.7
Total 158 100.0 227" 100.0
Slote. X2 (4) =2.88, £> = .58
“One respondent did not answer this item.
The second aspect of this objective was to compare the participant and nonparti­
cipant groups based on employment status. This was accomplished using the Chi-square 
test of independence to determine if the two variables (whether they participated and 
whether they were employed full time, part-time, retired, unemployed, or medically 
disabled) were independent. The resulting calculated Chi-square value (x2<4)= 2.88, jj = 
.58) was not significant, indicating that the two variables were independent.
Objective two g (vi) was to describe and compare African Americans who have 
participated in clinical research trials and those who have not participated in clinical 
research trials based on their approximate household income. The first aspect was to 
describe the participant and nonparticipant groups based on approximate household in-
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come. The largest number (n = 37,24.2%) of the respondents in the participant group 
reported an approximate household income range of $70,000 and over per year. The 
largest number (n = 48, 22.0%) of the respondents in the nonparticipant group reported 
an approximate household income in the range of $20,000 - $29,999 per year (see Table 
43).
Table 43
Description of Participants and Nonparticipants in Clinical Research Trials bv Household 
Income Among African Americans
Household Income Participants Nonparticipants
n % n %
< $10,000 per year 17 11.0 35 16.1
$10,000-$19,999 24 15.7 38 17.4
$20,000-$29,999 28 18.3 48 22.0
$30,000-$39,999 16 10.5 26 11.9
$40,000-$49,999 13 8.5 17 7.8
$50,000-$59,999 18 11.8 24 11.0
$70,000 and above 37 242 30 13.8
Total 153* 100.0 2I8b 100.0
Note, x2<6) = 8.02,p =.24
‘Five respondents did not answer this item.
'Twenty respondents did not answer this item.
The second aspect of this objective was to compare the participant and nonparti­
cipant groups on approximate household income. This was accomplished using the Chi- 
square test of independence to determine if  the two variables (whether they participated 
and level of household income) were independent The resulting calculated Chi-square
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value (x2(6>~ 8.02, £ = .24) was not significant, indicating that the two variables were 
independent.
Objective two g (vii) part I was to describe and compare African Americans who 
have participated in clinical research trials and those who have not participated in clinical 
research trials based on distance they lived from the research center. The first aspect 
was to describe the participant and nonparticipant groups based on distance lived from 
the research center. The largest number (n = 49 ,31.6%) of respondents in the partici­
pant group indicated that they lived within 15 miles of the research center. Likewise, the 
largest number (n = 66,29.6%) of respondents in the nonparticipant group lived within 
15 miles o f the research center (see Table 44).
Table 44
Description of Participants and Nonparticipants in Clinical Research Trials bv Distance 
Live From Research Center Among African Americans
Distance Live from 
Research Center
Participants Nonparticipants
n % n %
Within 3 miles 27 17.4 30 13.4
Within 7 miles 41 26.4 61 27.4
Within 15 miles 49 31.6 66 29.6
Within 20 miles 19 12.3 33 14.8
> 20 miles 19 12.3 33 14.8
Total 155“ 100.0 223b 100.0
Note. x2(4>= 196, p =  .74
‘Three respondents did not answer this item. 
bFive respondents did not answer this item.
The next part of this objective was to compare the participant and nonparticipant 
groups based on distance they lived from the research center. This was accomplished
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using the Chi-square test of independence to determine if the two variables (whether they 
participated and distance lived from the research center) were independent. The result­
ing calculated Chi-square value (x2<4)= 1 -96, p = .74) was not significant, indicating that 
the two variables were independent.
Objective two g (vii) part II was to describe and compare African Americans 
who have participated in clinical research trials and those who have not participated in 
clinical research trials based on distance they worked from the research center. The first 
aspect was to describe the participant and nonparticipant groups based on distance 
worked from the research center. The largest number (n = 49,35.5%) of the respon­
dents in the participant group worked within 7 miles of the research center and the two 
response categories with the largest numbers (n = 50,26.3% each) of the respondents in 
the nonparticipant group worked within 7-15 miles of the research center (see Table 45).
The next part of this objective was to compare the participant and nonparticipant 
groups based on distance worked from the research center. This was accomplished 
using the Chi-square test of independence to determine if the two variables (whether they 
participated and distance worked from the research center) were independent. The 
resulting calculated Chi-square value (x2,5>= 12.29, j> = .03) indicated that the variables 
were not independent The nature of the association between the variables was such that 
greater proportions of the participants indicated that they worked at the research center 
and within 7 miles of the center. In contrast, among the nonparticipants, greater propor-
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Table 45
Description of Participants and Nonparticipants in Clinical Research Trials bv Distance
Work From Research Center Among African Americans
Distance Work from 
Research Center
Participants Nonparticipants
n % n %
At research center 10 7.2 3 1.6
Within 3 miles 25 18.1 36 19.0
Within 7 miles 49 35.5 50 26.3
Within 15 miles 28 20.3 50 26.3
Within 20 miles 11 8.0 24 12.6
> 20 miles 15 10.9 27 14.2
Total 138* 100.0 190b 100.0
Mote. X2(S)= 12.29, p = .03
"Ten respondents did not answer to this item.
Thirty eight respondents did not answer to this item.
tions indicated that they worked within 15 miles, within 20 miles, and more than 20 miles 
from the research center.
Objective two g (viii) was to describe and compare African Americans who have 
participated in clinical research trials and those who have not participated in clinical 
research trials based on overall health status. The first aspect was to describe the partici­
pant and nonparticipant groups based on overall health status. The largest number (n = 
55,34.8%) of respondents in the participant group indicated their overall health was 
good. The largest number (n = 97,42.7%) of respondents in the nonparticipant group 
indicated their overall health was good (see Table 46).
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Table 46
Description of Participants and Nonparticipants in Clinical Research Trials bv Overall
Health Status Among African Americans
Overall Health Status Participants Nonparticipants
n % n %
Good 55 34.8 97 42.7
Very Good 54 34.2 72 31.7
Excellent 32 20.2 33 14.5
Fair 17 10.8 19 8.4
Poor 0 0.0 6 2.7
Total 158 100.0 227* 100.0
Note, x2 d)= 8.20. p = .09
“One respondent did not answer to this item.
The next part of this objective was to compare the participant and nonparticipant 
groups based on their overall health status. This was accomplished using the Chi-square 
test of independence to determine if the two variables (whether they participated and 
overall health status) were independent. The resulting calculated Chi-square value (x2(4) 
= 8.20, p = .09) was not significant, indicating that the two variables were independent.
Objective Three
Objective three of the study was to determine if  a model existed that significantly 
increased the researcher’s ability to correctly classify subjects on their participation 
status in clinical research trials based on (1) knowledge of clinical research processes, (2) 
perceptions of clinical research purposes and procedures, (3) advantages and disadvan­
tages for the individual of participation in clinical research trials, (4) characteristics of 
current and past participation in clinical research trials, (5) exposure to selected experi-
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ences which are preliminary to participation in clinical research trials, (6) perceptions 
regarding  the need for selected changes in preparation for participation in clinical 
research trials, and (7) the following selected personal demographic characteristics: (i) 
gender, (ii) age, (iii) marital status, (iv) education level, (v) employment status, (vi) 
household income, (vii) distance from research center, and (viii) overall health status.
To accomplish objective three of the study, the researcher examined the data for 
the existence of a statistically significant discriminant model. This model included all 
available information and was for the purpose of maximizing the researcher’s ability to 
correctly classify subjects on the outcome measure of whether or not African Americans 
participated in a clinical research trial. In addition, this model included all summary 
perceptual items measured in the study as well as selected demographic information.
The alpha level was established a'priori at .05 and substantive significance of the 
discriminant model in this study was defined as a 25% improvement over chance, the 
acceptable margin for a two category variable (Barrick and Warmbrod, 1988).
The Discriminant Model 
The first step in examining the discriminant model was to compare the groups on 
each of the independent variables. This information is presented in Table 47. 
Comparisons were made using the one-way analysis of variance procedure. Of the 43 
factors on which comparisons were made, the groups (participants and nonparticipants) 
were found to be significantly different on 16 variables. The variables on which the 
groups were most different were: knowledge factor one (“Information Provided”),
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Table 47
Comparison of Mean Values for Discriminating Variables in the Model bv Participation
Status Among African Americans
Discriminating
Variable
Group F ratio E
Participants Nonparticipants
VERBALY m 1.90 m 1.54 51.90 <.01
(Did you receive sd .30 sd .50
any verbal
materials, Yes)
VERBALN 1.06 1.37 44.25 <.01
(Did you receive .23 .48
any verbal
materials, No)
AGEGRP4 .48 .25 18.22 <.01
(46-55 years) .50 .43
AGEGRP2 .06 .25 17.96 <.01
(26-35 years) .25 .43
KFACTOR1 4.22 3.85 17.31 <.01
(Information .66 .79
Provided)
DISADVAN 2.74 3.17 16.20 <.01
(Drawbacks) .84 .92
KFACTOR2 4.58 4.33 16.17 <.01
(Awareness) .47 .58
FAMILYY 1.46 1.24 15.70 <.01
(Did you talk to .50 .43
family, Yes)
PFACTOR1 4.40 4.18 10.53 .001
(Participation .54 .55
Benefits)
FAMILYN 1.52 1.70 9.22 .003












ADVAN 3.98 3.79 7.72 .00
(Primary Benefits) .61 .55
WIDOWED 1.07 1.02 5.33 .02
(Marital Status) .26 .13
PFACTOR2 3.34 3.05 5.24 .023
(Prevention) 1.07 1.05
SOMECOLL .32 .45 5.20 .02
(1-3 yrs. College) .47 .50
HEALTH 2.31 2.52 4.27 .04
STATUS .86 .89
POSTGRAD .23 .15 3.72 .06
(Post graduate) .43 .35
HISTORYY 1.47 1.36 3.59 .06
(Did you have a .50 .48
family history, Yes)
WORK20 .06 .13 3.10 .08
(Within 20 miles) .25 .33
WORK 15 .20 .28 2.63 .11
(Within 15 miles) .40 .45
LIVE3 .17 .11 2.20 .14
(Within 3 miles) .38 .31
LESS10 .08 .13 2.00 .16
(Household income .27 .34
<$10,000/year)
WORKMORE .09 .14 1.75 .19
(> 20 miles) .29 .35
AGEGRP3 .27 .35 1.67 .20
(36-45 years) .45 .48
LIVE20 .13 .18 1.47 .23
(Within 20 miles) .34 .39
(Table continues)
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RETIRED 1.05 1.02 1.23 .27
(Employment .22 .15
status)
DOCTORY 1.15 1.11 1.23 .27
(Did you talk to .36 .31
your doctor, Yes)
fflSTORYN 1.48 1.54 .87 .35
(Did you have a .50 .50
family history, No)
COLLEGE .26 .22 .62 .43
(College degree) .44 .41
RECRUIT 4.14 4.08 .61 .44
(Ideas/Suggestions') .65 .64
LIVEMORE .10 .13 .54 .46
(More than 20 .31 .34
miles)
PARTTIME 1.07 1.10 .53 .47
(Employment .26 .30
status)
GENDER 1.77 1.80 .48 .49
.43 .40




DIVORCED 1.23 1.27 .40 .53
(Marital status) .43 .44




LIVE 15 .32 .30 .22 .64
(Within 15 miles) .47 .46
(Table continues)
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DOCTORN 







AGEGRP5 .10 .08 .12 .73
(56-65 years) .30 .28
DISABIL 1.02 1.01 .08 .77
(Medical disability) .13 .11
TWENTY30 .19 .21 .07 .79
(Household income, .40 .41
$20-$29,999/year)
SINGLE 1.19 1.19 .03 .86
(Marital status) .39 .40
knowledge factor two (“Awareness”), disadvantage factor (“Drawbacks”), whether or 
not they responded “Yes” to the question “Did you receive any verbal or written 
materials that described what the clinical trial was about and what you would need to 
do,”whether or not they responded “No” to the question “Did you receive any verbal or 
written materials that described what the clinical trial was about and what you would 
need to do,”whether or not they responded “Yes” to the question “Did you have a family 
history o f the disease being researched that prompted your decision to participate or not 
participate,” whether or not they responded “No” to the question “Did you have a family 
history o f the disease being researched that prompted your decision to participate or not 
participate, whether or not they were in the 26-35 year age group, and whether or not 
they were in the 46-55 year age group.
After comparing the discriminating variable means, the next step in conducting a 
discriminant analysis was to examine the independent variables to be included in the 
analysis for the presence of multicollinearity. Several techniques are available for con-
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ducting this assessment, however, Lewis-Beck (1980) indicates that the preferred 
method for assessing multicollinearity is to, “Regress each independent variable on all the 
other independent variables” (p. 60). This procedure takes into account the relationship 
of each of the independent variables with all of the other independent variables. If any of 
the cumulative R2 values are near 1.0, there is high multicollinearity. It is also important 
to note that values which are considered to be high in multicollinearity are more stringent 
for studies which have small sample sizes, while larger sample sizes reduce the serious­
ness of the consequences of multicollinearity. When the cumulative R2 was checked for 
each of the independent variables regressed on all the other included independent 
variables, no instances of excessive multicollinearity were found.
In the third step, the computed standardized canonical discriminant function co­
efficients were examined. The centroids for the groups were determined to be .75 for 
the participant group and -.56 for the nonparticipant group. A total of 7 factors entered 
the discriminant model and produced an overall canonical correlation of R = .544. This 
indicated that the combination of the 7 factors in the model explained a total of 29.6%
(R2) of the variability in whether or not African Americans participated in clinical 
research trials.
The factors which were found to have the highest standardized coefficients were 
(1) knowledge factor 2 labeled by the researcher as “Awareness”, (2) disadvantage 
factor labeled by the researcher as “Drawbacks”, (3) “Did you receive any verbal or 
written materials that described what the clinical trial was about and what you would 
need to do” (whether or not they responded “Yes”), (4) whether or not their marital 
status was Widowed, (5) whether or not they were in the 26-35 year age group, (6)
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whether or not they were in the 46-55 year age group, and (7) whether or not their place 
of employment was within 15 miles of the Pennington Center. Each of the factors that 
entered this model was statistically significant. When the structure coefficients were 
examined for substantive significance, five of the factors were found to meet the criteria 
of substantive significance. This criteria includes all factors which are one-half or larger 
of the magnitude of the largest structure coefficient. However, since the purpose of this 
model was to increase the researcher’s ability to correctly classify subjects on their 
participation status in clinical research trials, all variables were retained that met the 
statistical criteria for inclusion (see Table 48).
Table 48
Summary Data for Stepwise Discriminant Analysis (n = 3111
Variables b s Discriminant Centroids 
Group
VERBALY 
(Did you receive 
any verbal 
materials, Yes)























Sieen value Rc Wilk’s Lambda
.420 .544 .704
b = standardized discriminant function coefficient 
s = within group structure coefficient 
Rc = canonical correlation coefficient
Finally, the correctly classified cases were examined. Seventy five (19.4%) of the 
subjects were eliminated from the calculation of the discriminant model due to at least 
one missing discriminating variable. A total of 311 respondents were used in the 
calculated discriminant model. The researcher directed the classification portion of the 
program to classify all cases by using the mean-substitution function for missing values. 
This procedure functions as an additional check for the effectiveness of the model. The 
model correctly classified 74.6% of the cases analyzed (see Table 49).
Table 49
Classification of Cases bv the Discriminant Model for Participation Status of Potential 
African Americans in Clinical Research Trials
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To determine the substantive value of the derived discriminant model, the
researcher used the Tau statistic. This statistic measures the proportional reduction in
error and provides a standardized measurement of improvement from the model for any
number of dependent variable groups (Barrick and Warmbrod, 1988). It is calculated
using the following formula:
tau= ^ - E p a  
n -LP.n,
where: n,. = number of cases correctly classified 
n = total number of cases 
Pi = prior probability of group membership 
nj = number of cases in group i
A measurement of 25 or higher is generally considered to be indicative of a meaningful




tau= 232 - (67.5 + 88)
311 -(67.5 + 88)
tau = 232 - 155.5 
311-155.5 
tau = 76.5 
155.5
tau = 49.2
The 49.2 derived Tau was greater than the minimum value which indicates that the 
model is meaningful.
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CHAPTER 5 
SUMMARY
The purpose of this study was to gain an understanding of the knowledge, 
attitudes, and beliefs African Americans have that support decisions to either participate 
or not participate in a clinical trial.
Objectives
The following specific objectives were formulated to guide the researcher:
1. To describe African Americans who were potential participants in clinical research 
trials on each of the following perceptual and demographic measures:
a. Knowledge of clinical research processes;
b. Perceptions of clinical research purposes and procedures;
c. Advantages and disadvantages for the individual of participation in clinical 
research trials;
d. Characteristics of current and past participation in clinical research trials;
e. Exposure to selected experiences which are preliminary to participation in clinical 
research trials;
f. Perceptions regarding the need for selected changes in preparation for par­
ticipation in clinical research trials; and
g. Perceptions regarding the need for selected changes in preparation for par­
ticipation in clinical research trials; and









vii. Distance from research center, and
viii. Overall health status.
2. To describe and compare African Americans who have participated in clinical 
research trials and those who have not participated in clinical research trials on each 
of the following perceptual and demographic measures:
a. Knowledge of clinical research processes;
b. Perceptions of clinical research purposes and procedures;
c. Advantages and disadvantages for the individual of participation in clinical 
research trials;
d. Characteristics of current and past participation in clinical research trials;
e. Exposure to selected experiences which are preliminary to participation in clinical 
research trials;
f. Perceptions regarding the need for selected changes in preparation for par­
ticipation in clinical research trials; and
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v. Employment status,
vi. Household income,
vii. Distance from research center, and
viii. Overall health status.
3. To determine if  a model existed that significantly increased the researcher’s ability to 
correctly classify volunteers on their participation status in clinical research trials 
from the following perceptual and demographic measures:
a. Knowledge of clinical research processes;
b. Perceptions of clinical research purposes and procedures;
c. Advantages and disadvantages for the individual of participation in clinical 
research trials;
d. Characteristics of current and past participation in clinical research trials;
e. Exposure to selected experiences which are preliminary to participation in clinical 
research trials;
f. Perceptions regarding the need for selected changes in preparation for par­
ticipation in clinical research trials; and
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vii. Distance from research center, and
viii Overall health status.
The survey method was utilized in this study. The target population was defined 
as all African Americans age 18 and older who were potential participants in a clinical 
trial. The accessible population were all African Americans in the Pennington Biomedi­
cal Research Center’s Database from 1992-2000. The frame of the accessible population 
was established as those who were currently enrolled at the time of the study, previously 
participated, and those who did not participate in a clinical trial. The sample consisted of 
100% of the defined accessible population frame.
A modified version of the questionnaire (Appendix B) “Perceptions of Participa­
tion in Clinical Research” (McLean and Jensen, 1998) was utilized in conducting this 
study. The original questionnaire was modified due to the relevance of questions 
applicable to African Americans, length of the instrument, and the approximate time it 
would take to complete. The modified version of the questionnaire consisted of 8 pages, 
58 questions, and 7 sections.
The questionnaire was mailed to 3302 African American adults (770 participants 
and 2532 nonparticipants) who were potential participants in a clinical trial at the 
Pennington Biomedical Research Center during the years of 1992-2000. A letter of 
introduction (Appendix A) accompanied the questionnaire. Along with instructions and 
guidelines, the letter stressed the importance of completing the survey. Participants were 
asked to return questionnaires within two weeks after receiving. A total o f386 (158 
participants or 21 percent, and 228 nonparticipants or 9 percent) responded to the 
questionnaire.
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The following is a summary of the major findings in the study:
1. Knowledge nf clinical research processes- Overall respondents most strongly 
agreed with the item, "Volunteers can refuse to participate in a clinical trial". 
When comparing the participant group to the nonparticipant group, the item 
with which both groups strongly agreed was, "Volunteers can refuse to partici­
pate in a clinical trial". However, the item with which the participant group 
exhibited the lowest level of agreement was, "Volunteers are made aware of 
any possible complications or side effects of taking part in a clinical trial." The 
nonparticipant group expressed the lowest level of agreement with the item, 
"Volunteers usually receive a cash stipend for participation in a clinical trial." 
To further summarize these findings, the researcher utilized the underlying 
constructs and the corresponding sub-scale scores derived from the factor 
analysis conducted in objective one of the study. Two sub-scale scores for the 
knowledge factor were derived. The first was labeled by the researcher as 
"Information Provided”. The participant group reported significantly higher 
levels of agreement in the "Information Provided" knowledge factor than did 
the nonparticipants. The second knowledge factor, labeled as "Awareness" by 
the researcher, produced similar results in that the participant group had a 
significantly higher level of agreement with the items in the "Awareness” 
knowledge factor than did the nonparticipants.
2. Perceptions of clinical research purposes and procedure- Overall respondents 
most strongly agreed with the item, "Participation in a clinical trial can help
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future generations,” and the statement with which respondents least agreed 
was, "Participation in a clinical trial can delay a disease.” To further 
summarize these findings, the researcher utilized the underlying constructs and 
the corresponding sub-scale scores derived from the factor analysis conducted 
in objective one of the study. Two sub-scale scores for the perception factor 
were derived. The first perception factor was labeled by the researcher as 
"Participation Benefits.” The participant group reported significantly higher 
levels of agreement with items in the "Participation Benefits" perception factor 
than did the nonparticipants. For the second perception factor labeled by the 
researcher as "Prevention,” the participant group had a significantly higher 
level of agreement with the items in the "Prevention" perception factor than did 
the nonparticipants.
3. Advantages for the Individual of Participation in Clinical Research Trials- 
Overall respondents most strongly agreed with the item, "Doing something that 
will help others,” and least agreed with the item, "Getting free medications.”
To further summarize these findings, the researcher utilized the underlying 
constructs and the corresponding sub-scale scores derived from the factor 
analysis conducted in objective one of the study. Only one sub-scale score was 
derived and labeled by the researcher as, "Primary Benefits." The participant 
group reported significantly higher levels of agreement with items in the 
"Primary Benefits” advantage factor than did the nonparticipants. In addition, 
respondents were asked to specify nther advantages they perceived for the 
individual of participation in clinical research trials. The participant group
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specified, "Learn about medicine and body,” and "Meeting others" as other 
advantages to participation in clinical trials. The nonparticipant group speci­
fied, "Knowledge obtained is beneficial," and "If a clinical trial helps find a cure 
for a particular disease," as other advantages to participation in clinical trials.
4. Disadvantages for the Individual nf Participation in Clinical Research Trials- 
Overall respondents most strongly agreed with the item, "Experiencing side 
effects of the treatment," and least agreed with the item, "Being treated like a 
"guinea pig" as disadvantages for the individual of participation in clinical 
research trials. To further summarize these findings, the researcher utilized the 
underlying constructs and the corresponding sub-scale scores derived from the 
factor analysis conducted in objective one of the study. Only one sub-scale 
score was derived and labeled by the researcher as, "Drawbacks." The nonpar­
ticipant group reported significantly higher levels o f agreement with items in 
the "Drawbacks" disadvantage factor than did the participants. In addition, 
respondents were asked to specify other disadvantages they perceived for the 
individual of participation in clinical research trials. The participant group 
specified, "Dates and times can’t be changed or rescheduled, inconvenient," 
"Forcing someone to overeat to maintain a specific weight; many studies too 
long," and "Trip to clinic" as other disadvantages for the individual of partici­
pation in clinical research trials. The nonparticipant group specified, "Risk to 
your health," "Getting to clinic," "Time consuming; inconvenient," "Overcom­
ing past atrocities where African Americans were deliberately infected (i.e. 
syphilis virus)," and "Not knowing if you are receiving treatment or sugar pill"
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as other disadvantages for the individual of participation in clinical research 
trials.
5. Characteristics of Current and Past Participation in Clinical Research Trials- 
Six aspects of clinical research participation status were examined. The first 
aspect was whether or not the respondents had ever been asked to participate 
in a clinical trial. The majority of the participant group indicated that they had 
been asked to participate in a clinical trial. In contrast, the majority of the non­
participant group indicated that they had not been asked to participate in a 
clinical trial. The second aspect was whether or not the respondents had 
previously participated in a clinical trial. The majority of the participant group 
indicated that they had previously participated in a clinical trial. In contrast, 
the majority of the nonparticipant group indicated that they had not previously 
participated in a clinical trial. The third aspect was whether or not the respon­
dents were currently enrolled in a clinical trial. The nature of the association 
between the variable was such that a greater proportion of the participant 
group indicated that they were currently enrolled in a clinical trial while a 
greater proportion of the nonparticipants indicated that they were not currently 
enrolled in a clinical trial. The fourth aspect was whether or not respondents 
would participate in future clinical trials if they had said "No", to ever been, 
previously, or currently enrolled in a clinical trial. There was no significant 
difference in these two variables indicating that the two variables were inde­
pendent. The fifth aspect was whether or not the respondents had ever decided 
not to participate in a clinical trial after being eligible. The nature of the
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association between the variables was such that a smaller proportion of the 
participant group indicated they decided not to participate in a clinical trial 
after being eligible while a greater proportion of the nonparticipants indicated 
they had decided not to participate in a clinical trial after being eligible. The 
sixth aspect of characteristics of current and past participation in clinical 
research trials was to select the primary reason respondents decided not to 
participate in a clinical trial after being eligible. Overall the reason respondents 
most often identified was, "Changed jobs, schedule would not permit" as the 
primary reason not to participate in a clinical trial. Respondents were also 
asked to specify other primary reasons for choosing not to participate in a 
clinical trial. The participant group indicated, "Busy schedule," "Illness in 
family," "Was not selected,", and "Didn’t lose weight" The nonparticipant 
group indicated, "Disqualification; eligibility criteria for the study," "Hours of 
participation were during work hours," "No transportation,", and "Friend 
talked me out of it" as primary reasons not to participate in a clinical trial. The 
results of the respondents’ other specified responses were not significant, 
indicating that the two variables (whether or not they had participated and if 
yes, other primary reason decided not to participate after being eligible) were 
independent.
6. Exposure to Selected Experiences Which are Preliminary to Participation in 
Clinical Research Trials- A total of four selected experiences preliminary to 
participation in clinical research trials were examined. The first exposure was 
whether or not the respondents received any verbal or written materials that
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described what the clinical trial was about and what was needed to be done. 
The nature of the association between the variables was such that a greater 
proportion of the participant group indicated that they had received verbal or 
written materials that described what the clinical trial was about and what was 
needed to be done while a greater proportion of the nonparticipants indicated 
that they had not received any verbal or written materials describing what the 
clinical trial was about and what was needed to be done. The second exposure 
to selected experiences, which are preliminary to participation in clinical 
research trials, was whether or not respondents talked to family or friends 
before making their decision to participate or not participate in a clinical trial. 
The nature of the association between the variables was such that more of the 
participant group indicated that they talked to family or friends before making 
their decision to participate or not participate while the majority of the nonpar­
ticipants indicated they did not talk to family or friends before making their 
decision to participate or not participate in a clinical trial. The third exposure 
was whether or not the respondents talked to their doctor before making their 
decision to participate or not participate in a clinical trial. The two variables 
(whether or not they participated and whether or not they talked to their 
doctor before making the decision to participate or not participate in a clinical 
trial) were not significant, indicating that the two variables were independent. 
The fourth exposure was whether or not the respondents had a family history 
of the disease being researched that prompted their decision to participate or 
not participate in a clinical trial. The two variables (whether or not they
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participated and whether or not they had a family history of the disease being 
researched that prompted their decision to participate or not participate in a 
clinical trial) were not significant, indicating that the two variables were 
independent. In addition, respondents were asked to specify other exposures 
to selected experiences, which are preliminary to participation in clinical 
research trials. The largest response from the participant group was, "Having 
family history of disease,” and the two largest responses from the nonpartici­
pant group were, "Never asked to participate,” and "Did not fit profile" as 
other specified exposures to selected experiences, which are preliminary to 
participation in clinical research trials.
7. Perceptions Regarding the Need for Selected Chances in Preparation for
Participation in Clinical Research Trials- Overall the statement with which the 
respondents most strongly agreed was, "Hearing about the good things that 
have been discovered from clinical trials," and least agreed was, "Informa­
tional meeting about the clinical trial, presented by the nurse.” When compar­
ing the participant group to the nonparticipant group, the item with which both 
the participant and nonparticipant group most strongly agreed was, "Hearing 
about the good things that have been discovered from clinical trials." The item 
with which the participant group least agreed was, "Informational meeting 
about the clinical trial presented by African Americans.” The item with which 
the nonparticipant group least agreed was, "Informational meeting about the 
clinical trial presented by the nurse." To further summarize these findings, the 
researcher utilized the underlying constructs and the corresponding sub-scale
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scores derived from the factor analysis conducted in objective one of the study. 
Only one sub-scale score was derived and labeled by the researcher as, "Ideas/ 
Suggestions." When comparing the participant group to the nonparticipant 
group based on the sub-scale score, there was no significant difference in the 
two groups. In addition, respondents were asked to specify other perceptions 
regarding the need for selected changes in preparation for participation in 
clinical research trials. The largest response specified from the participant 
group was, "More advertising in African American periodicals," "TV 
commercials with African Americans," and "Post newsletters in African 
American communities." The nonparticipant group specified, "Research about 
the test not just from African Americans but whomever has participated."
8. Demographic Characteristics
a) Gender- The majority of the respondents overall were female. Likewise, the 
majority of the respondents in both the participant and nonparticipant groups 
were female. The two variables (whether or not they participated and gender) 
were not significant, indicating that the two variables were independent
b) Age- The largest number of respondents was in the 46-55 year age group. 
Likewise, the largest number of respondents in the participant group was in the 
46-55 year age group, while the largest group of respondents in the 
nonparticipant group was in the 36-45 year age group. The nature of the 
association between the two variables (whether they participated and age) were 
significant, indicating that the variables were not independent.
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c) Marital Status- Approximately half of the respondents were married.
Likewise, approximately half of the respondents in both the participant and 
nonparticipant groups were married. In comparing the participant group to the 
nonparticipant group, the two variables (whether they participated and marital 
status) were not significant, indicating that the two variables were independent.
d) Education Level- The largest group of respondents overall and in both the 
participant and nonparticipant groups completed 1-3 years college/ 
business/technical school. In comparing the participant group to the 
nonparticipant group, the two variables (whether they participated and 
education levels) were significant, indicating that the variables were not 
independent.
e) Employment Status- The majority of respondents in both the participant and 
nonparticipant groups were employed full time. In comparing the participant 
group to the nonparticipant group, the two variables (whether they participated 
and employment status) were not significant, indicating that the two variables 
were independent.
f) Household Income- Overall, the largest group of respondents had a house-hold 
income in the range of $20,000 - $29,999 per year. The largest number of 
respondents in the participant group reported an approximate household 
income range of $70,000 and over per year, while the largest number of 
respondents in the nonparticipant group reported an approximate household 
income in the range of $20,000 - $29,9999 per year. In comparing the 
participant group to the nonparticipant group, the two variables (whether they
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participated and household income) were not significant, indicating that the 
two variables were independent.
g) Distance from Respondents Domicile to Research Center- The largest group of 
respondents overall and in both the participant and nonparticipant groups live 
within IS miles of the research center. In comparing the participant and 
nonparticipant groups, the two variables (whether they participated and 
distance lived from the research center) were not significant, indicating that the 
two variables were independent.
h) Distance from Respondents Worksite to the Research Center- The largest 
group of respondents overall and in both the participant and nonparticipant 
groups work within 7 miles of the research center. In comparing the 
participant and nonparticipant groups, the two variables (whether they 
participated and distance worked from the research center) were significant, 
indicating that the two variables were not independent.
i) Overall Health Status- The largest group of respondents overall and in both 
the participant and nonparticipant groups were in good health. In comparing 
the participant and nonparticipant groups, the two variables (whether they 
participated and overall health status) were not significant, indicating that the 
two variables were independent
9. The Discrim inant Analysis Model- The factors attributable to the success 
of this model were 1) knowledge factor "Awareness," 2) disadvantage factor 
"Drawbacks," 3) "Did you receive any verbal or written materials that described 
what the clinical trial was about and what you would need to do" (whether or not
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they responded "Yes"), 4) whether or not their marital status was Widowed, 5) 
whether or not they were in the 26-35 year age group, 6) whether or not they were 
in the 46-55 year age group, and 7) whether or not their place of employment was 
within 15 miles of the Pennington Center. As a result, this model correctly 
classified seventy five percent of the cases analyzed, which exceeded the minimum 
requirement The Post Hoc Tau test statistic further supported the model as 
meaningful in yielding almost double the minimum value required.
Conclusions. Implications, and Recommendations
1. African Americans who are potential participants in clinical research trials have 
high levels of knowledge in the dimension of awareness of issues surrounding 
clinical research trials.
This conclusion is based on the finding that the mean score for African Americans on the 
knowledge dimension labeled by the researcher as “Awareness” was 4.42 on a five-point 
scale. This finding suggests that African Americans were aware of their right to change 
their mind at any time and withdraw from a clinical trial and they can refuse to partici­
pate. This finding further indicates that the research center is clearly conveying the 
message that participation in a clinical research trial is voluntary to potential African 
American participants.
Based on this conclusion and these findings the researcher recommends that the 
Principal Investigator and research team of clinical research trials which focus on African 
Americans place an increased emphasis on issues that would potentially increase volun­
tary participation of African Americans in clinical research trials. Some of the ways this 
might be accomplished include: increasing the involvement of members of the research
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team in recruitment activities. The literature suggest that Investigators would do well to 
solicit and incorporate the suggestions of African American community members and 
potential participants in designing research protocols and recruitment strategies (Corbie- 
Smithetal., 1999).
2. African Americans who have been participants in a clinical research trial have
higher levels of knowledge regarding clinical research trials than those who 
have not participated.
This conclusion is based on the findings that the participant group have higher levels of 
knowledge on both the “Awareness” (t 3g4= 4.093, g < .001) and the “Information 
Provided” (t 3M= 4.943, g < .001) sub-scales of the knowledge scale than did the non­
participant group. Providing the information necessary for a decision to participate or 
not participate in a clinical research trial is supported by another study which showed 
that African Americans were interested primarily in being educated about the study and 
that lack of information was a primary reason they did not participate in clinical trials 
(Roberson, 1994). In addition, African Americans in another study requested broader 
education about the importance of and opportunities for participation in medical 
research (Corbie-Smith et al., 1999).
Based on this conclusion and these findings the researcher recommends that the 
Principal Investigators and research team of clinical research trials which focus on 
African Americans place an increased emphasis on education about clinical research trials 
in the African American community. Some of the ways this might be accomplished 
include: informational meetings through workshops and seminars to build trust through 
first acknowledging the abuses surrounding previous clinical research trials. This may
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prove to create an opportunity for dialogue to heal the breached trust represented by the 
Tuskegee Syphilis Study. The informational meetings should be held in African Ameri­
can neighborhoods to include churches, community centers, state and local public meet­
ings, and colleges or universities.
3. African Americans who have participated in a clinical research trial have more 
positive perceptions o f the “Participation Benefits” of clinical research trials 
than those who have not participated.
This conclusion is based on the finding that the participant group more strongly agreed 
with the items in the factor “Participation Benefits” than did the nonparticipant group. 
The mean score for the participant group was 4.39 (SD = .54) and for the nonparticipant 
group 4.19 (SD = .62) (t 384= 3.249, g < .001). Studies have shown that the belief in the 
benefit of participation is an indication that racial/ethnic groups are likely to be influ­
enced to enroll in clinical research trials with some assurance that treatment could 
improve survival (Roberson, 1994). Other investigators have shown that participants 
expect to obtain personal benefit while contributing knowledge to medical science for the 
good of society (Blumenthal, Sung, Coates, Williams, & Liff, 1995; Mattson, Curb, & 
McArdle, 1985; Robinson, Ashley, & Haynes, 1996).
Based on this conclusion and these findings the researcher recommends that the 
Principal Investigators and the research team of clinical research trials which focus on 
African Americans place an increased emphasis on publishing the results of all clinical 
trials whether successful or unsuccessful. This will serve the purpose of building addi­
tional trust, increasing awareness and providing information that will inevitably enhance 
recruitment of African Americans in clinical research trials. Some of the ways to publi-
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cize the results o f a clinical trial include: production of research final report summaries 
written in lay terminology, culturally sensitive, and published regularly in outlets that 
reach the African American community.
4. African Americans who have participated in a clinical research trial have more
positive perceptions regarding the advantages of clinical research trials than 
those who have not participated.
This conclusion is based on the finding that the participant group more strongly agreed 
with the items in the factor “Primary Benefits” than did the nonparticipant group. The 
mean score for the participant group was 4.03 (SD = .60) and for the nonparticipant 
group 3.83 (SD = .61) (t m = 3.179, j> = .002). Studies have shown that the perceived 
benefits of clinical research trial participation, medical monitoring and treatment (Aby, 
Pheley, & Steinberg, 1996; Cunny & Miller, 1994; Tangrea, Adrianza, & Helsel, 1992; 
Wilcox & Schroer, 1994) altruism (Aby et al., 1996; Cunny et al., 1994) and financial 
compensation (Bigorra & Banos, 1990; Cunny et al., 1994) were described by 
participants as important.
Based on this conclusion and these findings the researcher recommends that the 
Principal Investigators and research team of clinical research trials which focus on 
African Americans, place an increased emphasis on the benefits of participation in clinical 
research trials. The participant group in this study supported this increased emphasis by 
indicating “Other” perceived advantages for the individual of participation in clinical 
research trials. Some of the “Other” perceived advantages included: “Leam about 
medicine and body,” “Lose weight, medical exam,” and “aid research by being available.” 
These “Other” perceived advantages are seen as benefits to the individual of participation
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in clinical research trials. The perceived benefits of clinical research trials are further 
indicated by the nonparticipant group in this study. Some of the “Other” perceived 
advantages from the nonparticipant group included: “Knowledge obtained is beneficial,” 
“If clinical research trial helps find a cure for a particular disease,” and “Providing the 
proper information; discussing the Phase I, II, III, IV trial results and expected 
outcomes. Clients need to know all expectations and consequences.”
These “Other” perceived advantages by both the participant and nonparticipant 
groups indicated that the message from Principal Investigators and the research team of 
clinical research trials should be clear and focused such as, the results of the clinical 
research trial indicated a decrease in cholesterol levels, blood pressure, blood sugar, and 
weight loss.
S. African Americans who have not participated in a clinical research trial more
strongly agreed with potential disadvantages to the individual of participation 
in clinical research trials than those who have participated.
This conclusion is based on the finding that the nonparticipant group more strongly 
agreed with the items in the factor “Drawbacks” than did the participant group. The 
mean score for the nonparticipant group was 3.16 (SD = .90) and for the participant 
group 2.65 (SD = .87) (t 384 = -5.595, j> < .001). “Experiencing side effects of the 
treatment” was the item with which nonparticipants most strongly agreed.
Based on this conclusion and these findings the researcher recommends that Princi­
pal Investigators and research team of clinical research trials which focus on African 
Americans participate in all procedures required by the trial. If the research team mem­
bers have taken part in the clinical research trial processes and procedures they will have
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increased credibility and trust among African American participants. Studies have shown 
that a trusting relationship was important for African Americans to feel comfortable as 
participants in clinical studies (Corbie-Smith et al., 1991). Other authors have suggested 
that trust developed between a primary care provider and a patient is the only way fear 
of exploitation in research can be overcome (El-Sadr & Capps, 1992) and that lack of 
trust in the researcher is the primary barrier to African American participation in clinical 
trials (Mouton, Harris, Rovi, Solorzano, & Johnson, 1997). The nonparticipant group in 
this study supported this increased emphasis by indicating “Other” perceived disadvan­
tages for the individual of participation in clinical research trials. Some of the “Other” 
perceived disadvantages included: “Risk to your health,”“Overcoming past atrocities 
where African Americans were deliberately infected (i.e. syphilis virus),” and “Uncer­
tainty of integrity of researchers/study.”
These “Other” perceived disadvantages by both the participant and nonparticipant 
groups indicated that “Trip to clinic,” “Dates and times can’t be changed or rescheduled, 
inconvenient,” and “No benefits if in control group” sends a clear message to Principal 
Investigators and the research team of clinical research trials indicating that flexibility of 
clinic hours as well as location of additional research sites other than at the research 
center may prove to enhance recruitment and retention of potential African Americans 
for participation in clinical research trials.
6. African Americans who have participated in clinical research trials and received 
verbal or written materials that described what the clinical trial was about and 
what was needed are more likely to participate in future clinical research trials.
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This conclusion is based on the results obtained through comparison of mean values for 
discriminating variables by participation status among African Americans. The results of 
the one way analysis of variance (F3II,p  < .01) was highly significant in the model 
suggesting that increased participation in clinical research trials was based on African 
Americans receiving verbal or written materials describing what the clinical trial was 
about and what was needed. The literature coincides with this conclusion in that novel 
methods of transmitting information such as instructional videos alone, or in combination 
with the written form, have been shown to be preferred by patients (Agre, McKee, 
Gargon, & Kurtz, 1997).
Based on this conclusion and these findings the researcher recommends that Princi­
pal Investigators and research team of clinical research trials which focus on African 
Americans produce effective and innovative presentations culturally sensitive to include: 
graphics that illustrate the purpose, procedures, time commitments, benefits, and incen­
tives for participation. Studies have shown that people might be retained for clinical 
trials if they are informed, educated, and counseled (Roberson, 1994). This may also 
increase trust among African Americans especially if they feel as a result of participation 
in clinical research trials, that their contribution to the study was valuable.
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My name is Betty Kennedy. I am a Research Recruiter and graduate student in the 
School of Vocational Education at Louisiana State University, Baton Rouge, Louisiana. 
As a Research Recruiter at the Pennington Biomedical Research Center for seven years, 
the task of recruiting African Americans into clinical trials remains a challenge. Since 
African Americans are disproportionately affected and have a higher prevalence of high 
blood pressure, diabetes, and obesity, the goal to enroll African Americans into clinical 
trials is crucial, especially finding ways to delay or prevent these diseases from occurring. 
Therefore, I need your help so that I can become more precise and efficient at recruiting 
African Americans into clinical trials. I am conducting a study to determine the reasons 
African Americans do and do not participate in clinical research. The purpose of this 
study is to gain an understanding of the knowledge, attitudes, and beliefs African 
Americans have that either support their decision to participate or not participate in a 
clinical trial. The findings from this study may improve the recruitment of volunteers in 
future clinical research.
Your participation in this study will involve completing the enclosed questionnaire. It 
will take no more than 20 minutes for you to complete. Please do not put your name on 
the questionnaire or the return envelope. Ail replies will be kept confidential. No names 
will appear on the questionnaire, only a code number.
Participation in this study is strictly voluntary and returning the completed 
questionnaire will imply your consent. The responses will be stored in a locked filing 
cabinet under my control. The information that you provide will not be used for any 
purpose except for this study.
If you agree to participate, please complete and seal the questionnaire in the self- 
addressed stamped envelope provided. If you have any questions about this 
questionnaire, please contact me or my dissertation chair at the telephone numbers listed 
below. A copy of the completed study will be available at the School of Vocational 
Education (Old Forestry Building).
PLEASE RETURN THE COMPLETED QUESTIONNAIRE by: October 16,2009
Thank you in advancg, for your
Betty Kennedy, MPA, Ph.D.
Research Recruiter 
Pennington Biomedical Reses 
6400 Perkins Road 
Baton Rouge, Louisiana 708!
(225) 763-3090
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assistance in completing this questio.ti nnaire.
Candidate Dr. Geraldine Holmes
Associate Professor, Dissertation Chair 
irch Center Louisiana State University
127 Old Forestry BIdg.
>8-0025 Baton Rouge, Louisiana 70803
(225) 388-2464
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APPENDIX B
PERCEPTIONS OF PARTICIPATION IN CLINICAL RESEARCH 
(MODIFIED McLean & Jensen, 1998)
The questions in this survey are about “clinical trials research”.
A “clinical trial” is a research study that can be used to answer questions about new 
ways of both delaying and preventing diseases such as cancer, diabetes, heart disease, 
high blood pressure, and obesity. Researchers obtain funding through federal, state, and 
local means and generally utilize a research recruiter in obtaining volunteers to enroll in 
the study.
Instructions for Completing the Questionnaire
Please read each question carefully. There are no right or wrong answers. Please 
answer each question to the best of your knowledge. On a few questions, you will have 
space provided so that you can write out a specific answer. For most o f the statements 
you will be asked to select (1) strongly disagree, (2) disagree, (3) are unsure, (4) agree, 
or (5) strongly agree. By selecting “strongly disagree” you are saying that you do not 
believe or agree with the statement. By selecting “disagree” you are saying that although 
you may not strongly disagree with the statement, you are still not 100% sure of i t  By 
selecting “are unsure” you are saying that you do not know. By selecting “agree” you 
are saying that you don’t disagree with it. By selecting “strongly agree” you are saying 
that you believe or agree with the statement. Please circle or check where applicable, 
only one choice in response to each question or statement.
CONFIDENTIAL
THIS QUESTIONNAIRE CONTAINS 8 PAGES
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SECTION 1
The statements below are about your knowledge of clinical research. On a scale of 1-5, 
do you (1) strongly disagree, (2) disagree, (3) are unsure, (4), agree or (5) strongly agree 
as it relates to your knowledge of clinical research. Please circle only one choice per 
statement.
Strongly Disagree Unsure Agree Strongly 
Disagree Agree
1. Volunteers receive information 
needed to decide whether they want
to take part in a clinical trial. 1 2 3 4 5
2. Volunteers can refuse to 
participate in a clinical trial. 1 2 3 4 5
3. Volunteers can change their mind 
at any time and withdraw from a
clinical trial. 1 2 3 4 5
4. Volunteers are made aware of any 
possible complications or side effects
of taking part in a clinical trial. 1 2 3 4 5
5. Volunteers are told about the possible 
risks and benefits of taking part in a
clinical trial. 1 2 3 4 5
6. Clinical trials are needed to study the 
effects of treatments. 1
7. Volunteers usually receive a cash stipend 
for participation in a clinical trial. 1
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SECTION n
The following statements are about your perceptions of clinical research. On a scale of 
1-5, do you (1) strongly disagree, (2) disagree, (3) are unsure, (4) agree, or (5) strongly 
agree as it relates to your perceptions of clinical research. Please circle only one choice 
per statement.
Strongly Disagree Unsure Agree Strongly 
Disagree Agree
S. Clinical trials are a necessary
way to learn about treatments. 1 2 3 4 5
9. It is important for people to
take part in clinical trials. 1 2 3 4 5
10. The information in the consent 
form is important to help volun­
teers decide about participation 
in a clinical trial. 1 2 3 4 5
11. Participation in a clinical trial
can help me and my family. 1 2 3 4 5
12. Participation in a clinical trial 
can help future generations.
13. Blood work is necessary in a 
clinical trial.
14. Participation in a clinical trial 
can delay a disease.
15. Participation in a clinical trial 
can prevent a disease.
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SECTION in
Below is a list o f possible advantages and disadvantages of participating in a clinical 
trial. Your answers are very important whether you participated or decided not to 
participate in a clinical trial. On a scale of 1-5, do you (1) strongly disagree, (2) 
disagree, (3) are unsure, (4) agree, or (5) strongly agree with the advantages and 
disadvantages o f participating in a clinical trial. Please select only one choice per 
statement.
Strongly Disagree Unsure Agree Strongly
Disagree
Advantages of Participation
16. Receiving the newest treatment.
17. Doing something that will help others.
18. Getting free medications.
19. Helping to delay a disease.
20. Helping to prevent a disease.
21. Doing something positive for self.
22. Getting a cash stipend.
23. Getting better care and follow-up 
(for example, with laboratory tests)
24. Other advantages: (please
specify)____________________________
Disadvantages of Participation
25. Being treated like a “guinea pig”.
26. Having to miss work.
27. Having to arrange childcare.
28. Losing one’s privacy.
29. Experiencing side effects of the 
treatment
30. Disrupting one’s normal daily routine.
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SECTION IV
The questions in this section are about participants’ and non-participants’ current and 
past participation in clinical trials. Please check one appropriate choice.
32. Have you ever been asked to participate in a clinical trial?
1. YES □
2. NO □
33. Have you previously participated in a clinical trial?
1. YES □
2. NO □
34. Are you currently enrolled in a clinical trial?
1. YES □
2. NO □
35. If you said “No” to questions 32 through 34 above, and you were asked to 
participate in a clinical trial in the future, would you participate?
1. YES □
2. NO □
36. Have you ever decided not to participate in a clinical trial after being eligible? If 
no, go to Section V.
1. YES □
2. NO □
37. If  yes, what is the primary reason that you decided not to participate in the 
clinical trial? (Please check only one choice).
1. Changed jobs, schedule would not permit □
2. Changed mind, due to fear □
3. Live too far from research center □
4. Work too far from research center □
5. Too much effort involved □
6. Too many lab tests required □
7. Other (please specify)_________________
140
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
SECTION V
The next questions ask about who and what influenced your decision to participate or 
not participate in a clinical trial. Your answers are important whether or not you decided 
to participate in the trial. If you have been asked to participate in a clinical trial more 
than once, please refer to the most recent time. Please check one appropriate choice.
38. Did you receive any verbal or written materials that described what the clinical trial 














41. Did you have a family history of the disease being researched that prompted your 




42. Other (please specify)
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SECTION VI
Below is a list of ideas/suggestions for ways to help people leam more about clinical 
trials. Please indicate if you (1) strongly disagree, (2) disagree, (3) are unsure, (4) agree, 
or (5) strongly agree that the statement is an appropriate means of helping people leam 
more about clinical trials. Circle only one choice for each statement.
Strongly Disagree Unsure Agree Strongly 
Disagree Agree
43. Informational meeting about the
clinical trial, presented by the physician. 1 2 3 4 5
44. Informational meeting about the
clinical trial, presented by the nurse. 1 2 3 4 5
45. Informational meeting about the 
clinical trial, presented by African
Americans. 1 2 3 4 5
46. Hearing about the good things that have
been discovered from clinical trials. 1 2 3 4 5
47. Talking to other African Americans,
who have taken part in clinical trials. 1 2 3 4 5
48. TV shows or videotapes with African
Americans in clinical trials. 1 2 3 4 5
49. Other suggestions: (please specify)_____________________________
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SECTION v n
This section asks for some general information about you. Please note that all 
information is confidential. Your answers to the following questions will provide 
useful and valuable information for this study. Please check only one appropriate 
choice.
50. What is your gender?
1. MALE □
2. FEMALE □
51. What is your approximate age?
1. 18-25 years □
2. 26-35 years □
3. 36-45 years □
4. 46-55 years □
5. 56-65 years □
6. 66 years and over □
52. What is your marital status?
1. Married □
2. Divorced/Separated □
3. Never married □
4. Widowed □
53. Education (check the highest level completed)
1. Grades 0-8 □
2. Some High School □
3. High School diploma/GED □
4. 1-3 years college, business or technical school □
5. College degree □
6. Post graduate degree □
54. What is your present employment status?
1. Employed M l time (at least 36.5 hrs/week) □
2. Employed part-time (at least 20hrs/week) □
3. Retired □
4. Unemployed □
5. Medical disability □
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55. What is your approximate household income?
1. Less than $10,000 per year □
2. $10,000 - $19,999 per year □
3. $20,000 - $29,999 per year □
4. $30,000 - $39,999 per year □
5. $40,000 - $49,999 per year □
6. $50,000 - $59,999 per year □
7. $70,000 and above □
56. Approximately how far do you live from the Pennington Center?
(Check the shortest distance that applies).
1. Within 3 miles of the research center □
2. Within 7 miles of the research center □
3. Within 15 miles of the research center □
4. Within 20 miles of the research center □
5. More than 20 miles from the research center □
57. Approximately how far is your place of employment from the Pennington 
Center? (Check the shortest distance that applies).
1. At the research center □
2. Within 3 miles of the research center □
3. Within 7 miles of the research center □
4. Within 15 miles of the research center □
5. Within 20 miles of the research center □
6. More than 20 miles from the research center □
58. In general, would you say your health is:
1. Excellent □




Thank you for taking the time to complete the questionnaire!
Please seal this questionnaire in the self-addressed stamped envelope 
provided and return by: October 16,2000.
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I have forwarded on Louise's response to you. My name is 
mispeiled~it should read Donna McLean. I will forward a copy on to you 
once we receive some copies. Good luck with your research. Keep us posted 
we want to hear your comments of your experience.
Donna
---------------------- Forwarded by Donna McLean/UA/Nursing on 09/29/2000
04:53 PM ---------------------------





The modified version of the PPCR is fine with me. (Note that they spell 
your name correct). The article is supposed to be coming out Vol 12, No 1 
in Canadian Journal of Cardiovascular Nursing for them to reference. 
However, I do not know the page number yet. Tell Betty that you will send 
her a reprint as soon as you get them.
Louise
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APPENDIX D
PARTICIPANT RESPONSES
Question 24: Other Advantages
1. Learn about medicine and body. (9 responses)
2. Meeting others. (3 responses)
3. Don't know enough about this to make positive statements.
4. Lose weight, medical exam.
5. Aid research by being available.
Question 31: Other Disadvantages
1. Dates and times can't be changed or rescheduled, inconvenient (10 responses)
2. Forcing someone to overeat to maintain a specific weight; many studies are too long. 
(5 responses).
3. Trip to clinic. (4 responses)
4. Not getting free medicine for other condition.
5. No benefits if  in control group.
Question 37: Primary Reason Decided Not to Participate
1. Busy schedule. (4 responses)
2. Illness in family.
3. Was not selected.*
4. Didn’t lose weight.
*Each study has a different criteria; consequently, it’s possible to be eligible (selected) 
for one study and not be eligible for another.
Question 42: Other Influences on Your Decision to Participate or Not
1. Having family history of disease. (17 responses)
2 .1 wanted to find out what research was about
3. Unemployed (needed money); wanted to help people by doing study.
Question 49: Other Ideas/Suggestions
1. More advertising in African American periodicals, TV commercials with African 
Americans, post newsletters in African American communities. (9 responses)
2. Provide location for information and trial closer to individuals; have sites through out 
city instead o f one location. (3 responses)
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3. Flexible (longer) clinic hours: need to capitalize on first appointment because if people 
have to wait 2 weeks or so to see a doctor to receive medication- then they have lost 
their momentum/desire for losing weight or whatever reason for wanting to participate 
in the study. (3 responses)
4. Let African Americans know how this can help them and their family. (2 responses)
5. Informational meeting about clinical trial presented by African American physician.
(2 responses)




9. Meet with health center; occupational therapy; outpatient therapy.
10. Reveal side effects.
11. Physician needs to have excellent interpersonal skills.
12. Hard for participants to change or transition into documentation part of a study; 
seems to be a headache for the participant but needed for study. This needs to be 
explained more so persons can accept this responsibility more willingly so that you 
can get accurate and not made up data.
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APPENDIX E
NONPARTICIPANT RESPONSES
Question 24: Other Advantages
1. Knowledge obtained is beneficial. (11 responses)
2. If clinical trial helps find a cure for a particular disease. (5 responses)
3. Study more on sickle cell. (2 responses)
4. Providing the proper information; discussing the Phase I, II, III, IV trial results and 
expected outcomes. Clients need to know all expectations and consequences.
5. New treatment not always an advantage.
6. Low-income families need more help.
7. Staff is trustworthy.
8. Getting a cash stipend for completing lengthy questionnaires.
Question 31: Other Disadvantages
1. Risk to your health. (11 responses)
2. Getting to clinic. (7 responses)
3. Time consuming; inconvenient. (4 responses)
4. Overcoming past atrocities where African Americans were deliberately infected (i.e. 
syphilis virus). (3 responses)
5. Not knowing if you are receiving treatment or sugar pill. (3 responses)
6. Uncertainty of integrity of researchers/study.
7. Religious convictions.
Question 37: Primary Reason Decided Not to Participate
1. Disqualification; eligibility criteria for the study. (11 responses)
2. Hours of participation were during work hours. (9 responses)
3. No transportation.
4. Friend talked me out of it.
Question 42: Other Influences
1. Never asked to participate. (12 responses)
2. Did not fit profile. (12 responses)
3. To leam about health problem I had.
4. Financial need.
5. To help in scientific research.
Question 49: Other Ideas/Suggestions
1. Research about the test not just from African Americans but whomever has partici­
pated. (6 responses)
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2. Congregations; ask East Baton Rouge (EBR) Ministers Association to participate; 
have prominent African Americans of EBR community to do public service announce­
ments; take clinical trials to churches, contact schools for volunteers. (3 responses)
3. Provide list of side effects. (3 responses)
4. Endorsements from patients’ Primary Care Physician (PCP) would lend credibility to 
the trial. (2 responses)
5. Transportation, child care during screening visit, later appointments so that won’t 
have to miss work. (2 responses)
6. Talking to people who had good experiences with the trials; give all information to 
participants. (2 responses)
7. More TV commercials about clinic’s mission. (2 responses)
8. Explain how participation in clinical trials can possibly help you in prevention of a 
disease.
9. Not having to be present daily to eat meals; meet for labs on weekends only; have 
blood drawn at nearest hospital.
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VITA
The author was born in Orrville, Alabama, on September 6, 1952. She is the only 
child of Eliza Hardin. She is married to Mr. Roy Kennedy and has two beautiful 
children, Tiffany and Troy. She grew up in Mobile, Alabama, and graduated 
Valedictorian from Williamson High School in 1970.
The author received a Norton Biology Scholarship from Miles College, Birmingham, 
Alabama, and graduated with a bachelor of arts degree in biology/chemistry in May 
1973. After graduation, the author moved back home to Mobile, Alabama, and began 
training to become a Branch Manager of FinanceAmerica Corporation. Her training 
transferred her back to Birmingham, Alabama, as an Associate Manager, and finally, 
promoted and transferred to Baton Rouge, Louisiana, as a Branch Manager on July 18, 
1979.
After 15 years in the finance industry which had begun to fail, the author enrolled at 
Southern University in January 1990 and received the degree of Master of Public 
Administration in May 1992. Upon graduation, the author worked at the Office of 
Public Health, Chronic Disease Control, in New Orleans, Louisiana, for 9 months. She 
is currently employed at the Pennington Biomedical Research Center as a Research 
Recruiter for the past 8 years, has published 4 manuscripts, and recently received a 
$5,000 contract to recruit volunteers for Focus Groups giving her the privilege of 
serving as Principal Investigator.
Upon graduation with the degree of Doctor of Philosophy, she plans to continue on 
at the Pennington Biomedical Research Center as a researcher, recruiter, community 
activist, and ultimately, to teach in higher education.
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